European Neuropsychopharmacology (v.23, #S2)

P.3.c.003 Pharmacological modulation of Kv3 potassium channels regulates the firing of parvalbumin-positive fast-spiking interneurons by C.H. Large; M. Rosato-Siri; C. Virginio; E. Zambello; C. Mutinelli; G.S. Alvaro (S454-S455).

P.3.c.002 Disruption of low frequency oscillations by phencyclidine: mechanisms involved in antipsychotic reversal by L. Lladó-Pelfort; E. Troyano-Rodríguez; N. Jurado; F. Artigas; P. Celada (S454).

P.3.c.004 A mechanism of antipsychotic treatment failure and its reversal by D. Amato; F. Canneva; S. Maschauer; L. Chiofalo; S. Huber; A. Rümler; J. Kornhuber; S. Von Hörsten; O. Prante; C. Müller (S455).

P.3.c.006 Inhibitors of SNARE assembly as potential drugs for schizophrenia treatment: a screening study by A. Ramos-Miguel; A.M. Barr; A.J. Dwork; G.B. Rosoklija; J.J. Mann; N. Honson; T.A. Pfeifer; W.G. Honer (S456).

P.3.c.007 Increased oxidative stress in schizophrenic patients treated simultaneously with haloperidol and the second generation antipsychotics by V. Djordjevic; D. Lazarevic; L.J. Trajanovic; O. Zikic; V. Cosic; P. Vlahovic; B.V. Djordjevic (S456-S457).

P.3.c.001 Pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579 by F. Noël; T.E.T. Pompeu; F.R.S. Alves; C.D.M. Figueiredo; C.B. Antonio; V. Herzfeldt; S.M.K. Rates; E.J. Barreiro; C.A.M. Fraga (S453).

P.3.b.035 Temperament, character and neurological soft signs in patients with schizophrenia and unaffected siblings by F. Pastoriza; L. Galindo; D. Bergé; A. Mané; M. Picado; A. Bulbena; O. Vilarroya; C.R. Cloninger (S450).

P.3.b.034 Insight, treatment outcomes and recovery in first-episode schizophrenia by O. Agid; C.O. Siu; P.D. Harvey; R.B. Zipursky; G. Remington (S449).

P.3.b.037 Neuroinflammation in schizophrenia: a PET study with [18F]-FEPPA by M. Kenk; T. Selvanathan; N. Rao; I. Suridjan; P.M. Rusjan; A.A. Wilson; S. Houle; R. Mizrahi (S451).

P.3.d.002 Clinical predictors of therapeutic response to clozapine in a sample of 42 patients with treatment-resistant schizophrenia by J. Nakhli; L. Ltaief; L. Ben amor; S. Bouhlel; S. Ben Nasr; B. Ben Hadj Ali (S458-S459).

P.3.d.011 Reasons for aripiprazole discontinuation – a retrospective review by A. Millier; B. Briquet; N. Cadi-Soussi; V. Murthy; M. Toumi (S464).

P.3.d.010 The need for educating schizophrenic patients on the side effects of medications by Y. Hashimoto; S. Terawaki; T. Tanimizu; M. Hashimoto; M. Tensho (S463-S464).

P.3.d.013 Effect of risperidone or blonanserin on cognitive function and psychotic symptoms in patients with acute phase schizophrenia by H. Hori; K. Yamada; D. Kamada; Y. Shibata; A. Katsuki; R. Yoshimura; J. Nakamura (S465).

P.3.d.014 Efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia: a 13-week double-blind study by A. Wakamatsu; N. Takahashi; M. Takahashi; T. Saito; M. Iizumi; Y. Saito; H. Shimizu; T. Matsumura (S466).

P.3.d.009 Olanzapine versus risperidone: weight gain and BMI of schizophrenic patients in a 24-week trial by D. Siladji-Mladenovic; V. Knezevic; A. Ivezic; S. Drezgic-Vukic (S463).

P.3.d.008 Reproductive side effects of antipsychotic-induced hyperprolactinemia; a cross-sectional study – preliminary results by E. Rubio-Abadal; G. Saenz Navarrete; B. Arranz; N. Del Cacho; R. Cambra; R. Iniesta; M. Roca; V. Barneda; J. Usall (S462).

P.3.d.004 A 57-week, open-label evaluation of paliperidone palmitate flexible-doses in Japanese patients with schizophrenia by A. Wakamatsu; N. Takahashi; M. Takahashi; T. Saito; M. Iizumi; Y. Imai; Y. Saito; T. Matsumura (S459-S460).

P.3.d.005 Paliperidone palmitate versus conventional depots in patients with schizophrenia: a 12 months study by S.L. Romero Guillena; B.O. Plasencia Garcia de Diego; A. Fernandez Galvez (S460).

P.3.d.006 A randomized clinical trial of histamine 2 receptor antagonism in treatment resistant schizophrenia by K. Meskanen; H. Ekelund; J. Laitinen; P.J. Neuvonen; J. Haukka; P. Panula; J. Ekelund (S461).

P.3.d.007 Efficacy of cariprazine on PANSS items and Marder factors: post hoc analysis of a double-blind, placebo-controlled trial in schizophrenia by J. Kane; L. Citrome; R. Litman; S. Zukin; K. Lu; A. Ruth; K. Nagy; I. Laszlovszky; S. Durgam (S461-S462).

P.3.b.033 Drug and alcohol abuse or dependence in psychiatric inpatients by M.C. Garcia Mahia; E. Roman Fernandez; M. Vidal Millares (S448-S449).

P.3.b.013 Risperidone in long-acting injectable form and treatment-resistant schizophrenia with dopamine supersensitivity psychosis by H. Kimura; N. Kanahara; N. Komatsu; K. Muneoka; H. Yamanaka; T. Suzuki; H. Komatsu; Y. Sekine; H. Watanabe; M. Iyo (S436-S437).

P.3.b.014 Premorbid adjustment is different in bipolar disorder with psychotic symptoms and schizophrenia by P. Landi; G. Rutigliano; G. Papi; A. Callari; L. Dell'Osso; D. Marazziti (S437).

P.3.b.015 Validation of a technique for the determination of plasma cotinine levels in patients with first episode psychosis by M. Bustillo; A. Zabala; R. Segarra; J. García; J. Cartón; M. Alonso; B. Santos; A. Ugarte; A. Gonzalez-Pinto; M. Gutiérrez (S438).

P.3.b.016 Low low-density lipoprotein (LDL) as a predicting factor for early onset schizophrenia by V. Slavkovic; P.J. Nikolic; S. Manojlovic; D. Gugleta; V. Sibinovic (S438-S439).

P.3.b.010 Predictors of acute response to treatment in first episode of psychosis by A. Mane Santacana; D. Berge Baquero; P.C. Garnier Lacueva; P. Salgado Serrano; R. Cortizo Vidal; A. Bulbena Vilarrassa (S435).

P.3.b.006 NGF and BDNF as markers of long-term functionality in first-episode psychosis patients with/without cannabis consumption by M. Martinez-Cengotitabengoa; M. Saenz; M. Fernández; S. Ruiz de Azua; A. Ugarte; P. Vega; C. Bermúdez; A. García-Alocén; A. Gonzalez-Pinto (S432-S433).

P.3.b.005 Oxidative stress at the first psychotic episode: long-term implications by M. Martinez-Cengotitabengoa; S. Alberich; S. Barbeito; J.A. Micó; C. Arango; D. Fraguas; I. Gonzáxlez-Ortega; A. González-Pinto (S431-S432).

P.3.b.007 Duration of untreated psychosis and sexual dysfunction among male patients by V. Sibinovic; S. Tosic-Golubovic; V. Slavkovic; G. Selimovic; T. Mladenovic (S433).

P.3.b.017 Sex-differences in the relationship between cortisol awakening response and working memory in subjects with early psychosis by I. Montalvo; M. Creus; M. Solé; T. Feliu; J. Franch; E. Vilella; A. Gutiérrez-Zotes; J. Labad (S439-S440).

P.3.b.029 Antipsychotics, metabolic syndrome and schizophrenia: investigating the role of SREBF polymorphisms by M. Spangaro; R. Cavallaro; C. Guglielmino; F. Cocchi; C. Lorenzi; A. Pirovano; E. Smeraldi; M. Bosia (S446).

P.3.b.030 Change in the pharmacotherapy of schizophrenia patients over a period of 10 years by D. Ceylan; A. Aktener; B. Akdede; K. Alptekin (S446-S447).

P.3.b.031 Neuropsychological profile in psychosis risk syndrome in a child and adolescent sample by J. Tor; A. Sintes; O. Puig; C. Espelt; D. Muñoz; M. Rodríguez; E. De la Serna; B. Sánchez; M. Dolz; I. Baeza (S447-S448).

P.3.b.025 Relation between antipsychotic polypharmacy, symptom domains and the quality of life in schizophrenia and schizoaffective disorder by D. Ceylan; S. Yesilyurt; B. Akdede; A. Topuzoglu; Z. Sayin; M. Diriöz; K. Alptekin (S443-S444).

P.3.b.020 Description of clinical characteristics and treatment of a sample of adolescents with psychosis risk syndrome by I. Baeza Pertegaz; E. De la Serna; G. Sugranyes; O. Puig; V. Sánchez-Gistau; D. Ilzarbe; J. Tor; M. Espadas; M. Carulla; M. Dolz (S440-S441).

P.3.b.022 Structural differences between patients with persistent auditory verbal hallucinations and stable schizophrenic patients by A. Keymer; M. Serra; F. Nuñez; E.M. Grasa; A. Roldán; S. Vieira; E. Aguilar; G. García; B. Gómez; I. Corripio (S442).

P.3.b.023 Structural analysis of nucleus accumbens in antipsychotic-naive first episode psychosis and clinical correlations by F. Sem; D. Bergé; L. Igual; C. Canals; A. Mané; D. Guinart; O. Vilarroya; M. Forns (S442-S443).

P.3.f.001 Catechol-O-methyltransferase [rs4680] and methylenetetrahydrofolate reductase [rs1801133] polymorphisms interact on elevated plasma homocysteine in schizophrenia by D. Kontis; E. Theochari; S. Kleisas; E. Fryssira; C. Sofocleous; A. Gazi; D. Kypraios; L. Boniatsi; A. Chaidemenos (S492).

P.3.d.051 Lurasidone in the treatment of early-stage schizophrenia: a post-hoc analysis of three pooled acute treatment studies by J. Lieberman; A. Pikalov; J. Hsu; J. Cucchiaro; P. Werner; F. Grossman; A. Loebel (S488-S489).

P.3.d.047 Switching to lurasidone in patients with schizophrenia: tolerability and effectiveness at 6 weeks and 6 months by J.P. McEvoy; L. Citrome; D. Hernandez; J. Hsu; P. Werner; A. Pikalov; J. Cucchiaro; C.U. Correll; A. Loebel (S486).

P.3.d.048 Expected and effective plasma concentrations of antipsychotics and changes in psychopathology by A. Kaufmann; M.A. Rettenbacher; N. Yalcin; F. Biedermann; M. Edlinger; G. Kemmler; C.G. Widschwendter; S.W. Toennes; W.W. Fleischhacker; A. Hofer (S486-S487).

P.3.d.049 Expected and effective plasma concentrations of antipsychotic drugs and attitude toward treatment by N. Yalcin-Siedentopf; M.A. Rettenbacher; A. Kaufmann; F. Biedermann; M. Edlinger; G. Kemmler; F. Wartelsteiner; C.G. Widschwendter; W.W. Fleischhacker; A. Hofer (S487).

P.3.f.004 Three years follow-up in schizophrenic patients: predictors of recovery by D. Cannavò; C. Concerto; O. Bianchini; E. Aguglia (S493-S494).

P.3.f.013 Burden of diabetes and cardiovascular diseases in schizophrenia and bipolar patients: analysis of health registers in Sweden by N. Bent-Ennakhil; M.C. Périer; P. Sobocki; G. Johansson; D. Milea; J.P. Empana (S498-S499).

P.3.f.012 Association between bilirubin and schizophrenia: a longitudinal study by A. Hofer; C.G. Widschwendter; M.A. Rettenbacher; M. Edlinger; G. Kemmler; W.W. Fleischhacker (S498).

P.3.f.015 Abnormal functioning of the default mode network in schizophrenia and unaffected relatives: a study of functional magnetic resonance by L. Galindo; N. Roe; F. Pastoriza; D. Berge; M. Picado; A. Mane; A. Bulbena; O. Vilarroya (S500-S501).

P.3.f.016 AKT1 gene polymorphism and metabolic syndrome in patients with schizophrenia and bipolar disorder by T. Youn; N.Y. Lee; I.W. Chung; Y.S. Kim; S.H. Kim; Y.M. Ahn; H.S. Jun; E.K. Ji (S501).

P.3.f.006 Outpatient treatment of psychotic disorders – biological and general health data on antipsychotic treatment by A. Falces; R. Borrego; T. Sarmiento; M.J. Reyes; C. Conesa; T. Bel; T. Corominas (S494-S495).

P.3.f.007 Association between metabolic disease and cardiovascular risk in patients with schizophrenia treated with antipsychotics by A. Vataire; S. Ferchichi; K. Desroziers; N. Cadi-Soussi; V. Murthy; M. Toumi (S495).

P.3.d.025 Polypharmacotherapy in hospital treatment of schizophrenia by D.J. Siladji-Mladenovic; V. Knezevic; S. Drezgic-Vukic; A. Ivezic (S472-S473).

P.3.d.026 Comparative effectiveness of long-term treatment with atypical antipsychotics in patients with schizophrenia by A. Pikalov; L. Citrome; J. Hsu; P. Werner; J. Cucchiaro; A. Loebel (S473).

P.3.d.027 Aripiprazole once-monthly for schizophrenia: a double-blind, randomised, non-inferiority study versus oral aripiprazole by T. Peters-Strickland; W.W. Fleischhacker; R. Sanchez; N. Jin; R.A. Baker; B. Johnson; J.Y. Loze; R.D. McQuade; W.H. Carson; J.M. Kane (S473-S474).

P.3.d.028 Personal and social performance in schizophrenia: double-blind, non-inferiority study of once-monthly vs oral aripiprazole by W.W. Fleischhacker; R. Sanchez; N. Jin; T. Peters-Strickland; B.R. Johnson; A. Eramo; J.Y. Loze; R.D. McQuade; W.H. Carson; J. Kane (S474-S475).

P.3.d.022 Pharmacological treatment of acute agitation in schizophrenia by O. Bianchini; S. Porcelli; E. Aguglia; D. De Ronchi; A. Serretti (S470-S471).

P.3.d.018 Effect of the DRD2 polymorphisms on perospirone and aripiprazole efficacy for Japanese schizophrenia patients – Results of an RCT by Y. Takekita; M. Kato; S. Nonen; M. Wakeno; S. Sakai; G. Okugawa; J. Azuma; T. Kinoshita (S468).

P.3.d.017 Screening for metabolic risk factors in women treated for schizophrenia by B. Batinic; M. Djeric-Jeremic; D. Duisin; G. Opacic (S467-S468).

P.3.d.019 Reboxetine add-on to clozapine in treatment of negative symptoms of schizophrenia: a preliminary open-label study by D. Quattrone; A. Bruno; U. Micò; G. Pandolfo; G. Scimeca; M.R. Muscatello; R. Zoccali (S469).

P.3.d.020 Safety of blonanserin (BNS) and paliperidone extended-release (PAL-ER) in patients with acute schizophrenia by K. Sanada; A. Iwanami; K. Saito; T. Morita; K. Azuma; T. Yoshizawa; T. Tamura; A. Tsukurimichi; Y. Kawamura; E. Uchida (S469-S470).

P.3.d.029 Potential treatment with extended-release D2/D3 receptor agonist for tardive dystonia by A. Okato; H. Kimura; M. Takase; N. Kanahara; H. Watanabe; M. Iyo (S475).

P.3.d.030 Efficacy and safety of yokukansan (TJ-54) for treatment-resistant schizophrenia: a randomised placebo-controlled trial by T. Miyaoka; M. Furuya; J. Horiguchi; R. Wake; S. Hashioka; M. Toyama; T. Daimon; N. Mori; Y. Minabe; M. Iyo (S476).

P.3.d.041 Paliperidone combination treatment in clozapine-resistant schizophrenia by D. Karaiskos; E. Tzavellas; A. Liappas; I. Liappas; T. Paparrigopoulos (S482-S483).

P.3.d.042 Low doses of rotigotine in patients with antipsychotic-induced parkinsonism by C. Fini; S. Pallottino; C.L. Telesforo; F. Pompei; F. Pierelli; R. Di Fabio; S. De Filippis (S483).

P.3.d.037 Hospitalization rates in patients switched from oral antipsychotics to aripiprazole once-monthly for schizophrenia by J. Kane; J. Zhao; R.A. Baker; A. Eramo; R.D. McQuade; R. Sanchez; T. Peters-Strickland (S480).

P.3.d.031 Ten-year antipsychotic treatment – longitudinal study on metabolic parameters by F. Franza; N. Fiorentino; A. Soddu; V. Fasano; L. Calabrese; M. Iandoli; A. Battista; G. Del Buono (S476-S477).

P.3.d.033 Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, randomised, double-blind, placebo- and active-controlled trial by J.A. Lieberman; A.J. Cutler; S. Wan; R. Migliore; A. Ruth; I. Laszlovszky; G. Nemeth; S. Durgam (S477-S478).

P.3.d.034 How do we treat involuntarily admitted patients with schizophrenia? by B. Frajo-Apor; N. Schabetsberger; G. Kemmler; W. Fleischhacker (S478).

P.3.b.003 Therapeutic tactics in schizophrenia treatment in 1968–70 and 2010–12 by A. Savelyev; A. Lobko; V. Pashkovskiy; A. Sofronov (S430-S431).

P.2.d.034 Clock genes polymorphisms associations with suicide attempts in bipolar patients by M. Maciukiewicz; J. Pawlak; M. Dmitrzak-Weglarz; M. Wilkosc; A. Leszczynska-Rodziewicz; D. Zaremba; J. Hauser (S383-S384).

P.2.d.039 Serum thioredoxin levels in manic patients with psychotic symptoms by A. Genc; T. Kalelioglu; A. Tasdemir; N. Karamustafalioglu; F.C. Gungor; E.S. Genc; S. Incir; M. Emul; M.C. Ilnem (S386).

P.2.d.038 Cerebrospinal fluid cytokine concentrations in bipolar disorder patients and healthy controls by A. Isgren; J. Jakobsson; E. Pålsson; C.J. Ekman; A. Johansson; C. Sellgren; K. Blennow; H. Zetterberg; M. Landén (S385-S386).

P.2.d.028 Relating mood to plasma glutathione and BDNF levels in patients with bipolar disorder by N. Singh; A.R. Rosa; W. Whitaker; M. De Brito; A. Lewis; E. Vieta; G.C. Churchull; J.R. Geddes; G.M. Goodwin (S380).

P.2.d.027 Serum glycine and serine levels in patients with bipolar disorder by E. Pålsson; K. Södersten; H. Agren; K. Hashimoto; M. Landén (S379).

P.2.d.029 Serum matrix metalloproteinase-9 (MMP-9) and interferon gamma (IFN-γ) in bipolar mood disorder by A. Remlinger-Molenda; A. Czech-Kucharska; M. Wojcicka; M. Michalak; J. Losy; J.K. Rybakowski (S380-S381).

P.2.d.031 Quetiapine's effects on emotional processing and sleep oppose abnormalities seen in bipolar phenotype by P.L. Rock; C.J. Harmer; R.G. Foster; K. Wulff; G.M. Goodwin (S381-S382).

P.2.d.041 The benefit of physical activity as a treatment of bipolar disorder by E. Oberreither; S. Bengesser; N. Lackner; F. Fellendorf; A. Mitteregger; F. Kattnig; B. Reininghaus; H. Kapfhammer; S. Liebmann-Wallner; E. Reininghaus (S387-S388).

P.2.e.002 Vortioxetine (Lu AA21004), a multimodal antidepressant: differentiation from current antidepressants in animal models of depression by A. Mørk; A.L. Pehrson; C. Betry; D. David; Y. Li; M. Gulinello; S.C. Leiser; N. Haddjeri; C. Sánchez (S392-S393).

P.2.d.047 Efficacy and safety of asenapine for the treatment of bipolar disorder type I and co-morbid substance use disorders by M. Di Nicola; O. De Vita; M. Pettorruso; L. De Risio; M. Marconi; A. Bruschi; F. Ruggeri; G. Martinotti; G. Camardese; L. Janiri (S391-S392).

P.2.d.043 Mood stabilisation and oxidative stress parameters in bipolar disorder by S. Bengesser; N. Lackner; E. Oberreither; A. Birner; S. Liebmann-Wallner; S. Zelzer; H. Mangge; H.P. Kapfhammer; B. Reininghaus; E. Reininghaus (S388-S389).

P.2.d.044 Effect of adverse childhood experiences on white matter microstructure in bipolar disorder by I. Bollettini; S. Poletti; D. Radaelli; C. Locatelli; C. Colombo; F. Benedetti (S389).

P.2.d.045 Lithium during late pregnancy: pharmacokinetics and neonatal outcomes by A. Gonzalez-Rodriguez; M.L. Imaz; M. Guitart; A. Torres; E. Roda; F. Botet; M. Palacio; D. Soy; M. Torra; L.L. Garcia-Esteve (S390).

P.2.d.046 C-reactive protein is elevated in bipolar disorder by A.A. Dargél; R. Tamouza; C. Henry; F. Kapczinski; J. Oliveira; O. Godin; M. Leboyer (S390-S391).

P.2.d.026 Efficacy and safety of low- and high-dose cariprazine in patients with acute mania associated with bipolar I disorder by J.R. Calabrese; P.E. Keck; A. Starace; K. Lu; A. Ruth; I. Laszlovszky; G. Nemeth; S. Durgam (S378-S379).

P.2.d.025 Allopurinol for mania. A randomized trial of allopurinol versus placebo as add-on treatment in manic bipolar patients by S. Burshtein; M. Weiser; A.A. Gershon; G. Marian; N. Vlad; I.G. Grecu; E. Tocari; A. Tiugan; M. Hotineanu; J.M. Davis (S378).

P.2.d.007 Are comorbid insulin resistance and type II diabetes risk factors for refractory bipolar illness? by C. Calkin; M. Ruzickova; C. Slaney; J. Garnham; T. Ransom; M. Alda (S366-S367).

P.2.d.006 The MANACOR study on treatment effectiveness in mania by N. Cruz Culebra; C. Saez; M. Mur; E. Nieto; E. Vieta (S365-S366).

P.2.d.009 The predictive role of Val66Met polymorphism on levels of BDNF along treatment of medication-free patients with bipolar disorder by I. Grande; P. Magalhães; I. Chendo; L. Sterzt; G. Fries; K. Cereser; M. Kunz; B. Frey; E. Vieta; F. Kapczinski (S367-S368).

P.2.d.010 Breaking bad news – a valproate reaudit by H. Atturu; D. Odelola; E. Etuk; S. Harris (S368-S369).

P.2.d.005 Comparison of treatment of bipolar disorder between the Venezuelan cohort and the total population of a large multinational longitudinal study (WAVE-bd) by M. Bifano; T. Baptista; X. Vilema; X. Mazzarella; I. Carreira; C. Montes; S. Beluche; E. Vieta (S365).

P.2.c.013 Effect of the putative lithium-mimetic ebselen on 5-HT neurochemistry in the mouse brain by I. Antoniadou; T. Fowler; E. Cardici; T. Arsiwala; T. Sharp (S362).

P.2.c.012 Evaluation of peripheral biomarkers in bipolar and unipolar depression by B. Schilling Panizzutti; B. Wollenhaupt-Aguiar; B. Pfaffenseller; L. Spanemberg; M.A. Caldieraro; E.A. Vares; M.P. Fleck; M. Kunz; F. Kapczinski; M. Kauer-Sant'Anna (S361-S362).

P.2.d.001 Neurocognitive impairments in bipolar disorder are restricted to a subgroup of patients by T. Sparding; K. Silander; S. Hansen; M. Landén (S362-S363).

P.2.d.003 Fractional anisotropy in patients with first episode mania in late life by J. Ramirez-Bermudez; P. Alvarado; O. Marrufo; C. Berlanga; A. Guadamuz; C. Atriano; R. Carrillo; J. Taboada; R. Perez-Esparza (S363-S364).

P.2.d.011 Asenapine versus olanzapine in patients with acute mania by S.L. Romero Guillena; B.O. Plasencia Garcia de Diego; P. Aguilar Valseca; E. Garcia Henche; P. Vaquero Casado; N. Casas Barquero (S369).

P.2.d.012 Clinical implications of the polarity index of drugs in maintenance treatment of bipolar disorder: a naturalistic study by D. Popovic; C. Torrent; C.M. Bonnin; A.M.A. Nivoli; A. Murru; I. Pacchiarotti; M. Valenti; E. Vieta (S369-S370).

P.2.d.020 The effectiveness of asenapine in clinical practice: the EXPASEN study by A. Murru; N. Cruz; A. Gonzalez-Pinto; C. De Dios; J.M. Montes; A. Perez; I. Zorrilla; P. Lopez; E. Vieta (S374-S375).

P.2.d.023 Associations between cerebrospinal fluid markers and on-going medical treatment in patients with bipolar disorder by J. Jakobsson; E. Pålsson; M. Bjerke; B. Olsson; C.J. Ekman; C. Sellgren; A.G.M. Johansson; K. Blennow; H. Zetterberg; M. Landén (S376-S377).

P.2.d.024 Long-term safety and tolerability of open-label cariprazine in patients with bipolar I disorder by T.A. Ketter; G.S. Sachs; K. Lu; A. Ruth; I. Laszlovszky; K. Nagy; A. Starace; S. Durgam (S377).

P.2.d.019 Asenapine in the treatment of bipolar 1 disorder: a 12 months study by A. Fernandez Galvez; S.L. Romero Guillena; M.E. Dominguez Ballesteros (S374).

P.2.d.018 Initial and post-treatment serum levels of total oxidant-antioxidant status and oxidative stress index in patients with manic episode by T. Kalelioglu; A. Genc; A. Tasdemir; N. Karamustafalioglu; F.C. Gungor; A. Cansiz; S. Incir; M. Emul; M.C. Ilnem (S373-S374).

P.2.d.014 Genetic variability at IMPA2 and INPP1 genes is associated to lithium response in bipolar patients by E. Jimenez; B. Arias; M. Mitjans; J.M. Goikolea; P.A. Saiz; M.P. Garcia-Portilla; P. Buron; J. Bobes; E. Vieta; A. Benabarre (S370-S371).

P.2.d.013 Clinical factors associated with rapid cycling bipolar disorder by M. Valentí; I. Pacchiarotti; E. Vieta (S370).

P.2.d.015 Cognitive deficits in obese bipolar patients – the impact of body fat distribution by N. Lackner; S. Bengesser; A. Birner; B. Reininghaus; F. Kattnig; F.T. Fellendorf; A. Mitteregger; E. Oberreither; S.J. Wallner-Liebmann; H.P. Kapfhammer; E.Z. Reininghaus (S371-S372).

P.2.d.017 Is hyperthymic temperament an alarming sign? by P. Marinova; L.G. Hranov (S372-S373).

P.2.f.001 The effect of antidepressant treatment on quality of life in patients with depressive disorders by H.C. Kim; S.K. Hwang; M.J. Lee; H.J. Jo; T.H. Jun; M.S. Lee; J.M. Kim; H.W. Yim; J.B. Kim (S396).

P.2.h.006 Emotional stability and openness are associated with severity of depressive and anxiety symptoms in patients with brain tumors by A. Bunevicius; S. Tamasauskas; A. Tamasauskas; V. Deltuva; R. Bunevicius (S418-S419).

P.2.h.009 Assessing psychopathological onset and delay to treatment through the “Psychopathological Onset Latency and Treatment Questionnaire” by L. Oldani; B. Dell'Osso; G. Spagnolin; G. Camuri; B. Benatti; C. Palazzo; C. Arici; C. Dobrea; N. Suardi; A.C. Altamura (S420-S421).

P.2.h.011 Somatic comorbidity in psychiatric outpatients with affective and anxiety disorders by M.C. Garcia Mahia; E. Roman Fernandez; J. Vicente Alba; M. Vidal Millares (S421).

P.2.h.002 Comparison of electrocardiogram parameters between lithium-well bipolar patients and healthy controls by K. Altinbas; S. Guloksuz; I.M. Caglar; F.N. Turhan Caglar; E. Kurt; E.T. Oral (S416).

P.2.h.003 Transcranial magnetic stimulation in major depression and vascular depression by C. Concerto; M.C. Costanzo; D. Cannavò; G. Lanza; M. Pennisi; E. Aguglia (S416-S417).

P.3.a.001 Familial liability to psychosis is associated with attenuated dopamine stress signaling in ventromedial prefrontal cortex by J. Lataster; D. Collip; J. Ceccarini; D. Hernaus; D. Haas; L. Booij; J. Van Os; J. Pruessner; K. Van Laere; I. Myin-Germeys (S421-S422).

P.3.a.010 Large scale quantitative proteomic analysis in human postmortem dorsolateral prefrontal cortex tissue in schizophrenia by R. Pinacho; N. Villalmanzo; J.J. Meana; M. Romeu; J.M. Haro; J. Villén; B. Ramos (S427-S428).

P.3.a.012 Altered default mode network activity in schizophrenia patients by A. Pankow; L. Deserno; F. Bermpohl; M. Walter; F. Schlagenhauf; A. Heinz (S428-S429).

P.3.b.001 Pharmacological management of alcohol dependence in chronic schizophrenia by D. Vasile; O. Vasiliu; A.G. Mangalagiu; B.M. Petrescu; G.A. Sopterean; R.E. Bratu (S429).

P.3.a.009 SP1 and SP4 transcription factors are increased in the postmortem hippocampus of subjects with chronic schizophrenia by R. Pinacho; V. Villalmanzo; E. Valdizán; E. Castro; A. Berengueras; J.M. Haro; I. Ferrer; B. Ramos (S426-S427).

P.3.a.004 Phencyclidine activates thalamocortical networks by inhibiting GABAergic neurons in the reticular nucleus of the thalamus by E. Troyano-Rodríguez; N. Santana; L. Lladó-Pelfort; P. Celada; F. Artigas (S423-S424).

P.3.a.003 Decreased functionality of lymphocyte dopamine transporter (DAT) in psychoses by D. Marazziti; A. Callari; P. Landi; S. Silvestri; M. Picchetti; S. Baroni (S423).

P.3.a.005 A deeper look onto schizophrenia mechanisms. Association with immunological related pathway by M. Calabrò; A. Drago; A. Sidoti; A. Serretti; C. Crisafulli (S424).

P.3.a.006 Risk for suicide in male schizophrenia patients and the moderating effect of IQ by R. Yoffe; O. Kapara; N. Werbeloff; A. Reichenberg; K. Ginat; E. Fruchter; M. Davidson; M. Weiser (S425).

P.2.f.030 Are there differences in treatment of acute manic episodes in bipolar patients with or without comorbid borderline personality disorder? by D. Barral; M. Castrillo; B. González; V. Sánchez; M. Rosique; L. López; N. Cruz (S412-S413).

P.2.f.011 Serum levels of BDNF, BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine (MRT) with major depressive disorder (MDD) by A. Katsuki; R. Yoshimura; H. Hori; W. Umene-Nakano; A. Ikenouchi-Sugita; K. Hayashi; K. Atake; J. Nakamura (S402).

P.2.f.014 PPP3CC gene in antidepressant response: results from three independent samples by C. Fabbri; D. Albani; R. Calati; C. Crisafulli; S. Kasper; J. Zohar; D. Souery; S. Montgomery; J. Mendlewicz; A. Serretti (S403).

P.2.f.015 A prospective study of escitalopram in treatment resistant depression not responding to venlafaxine by R. Calati; D. Souery; S. Montgomery; S. Kasper; J. Zohar; J. Mendlewicz; A. Serretti (S403-S404).

P.2.f.004 Quantitative EEG cordance, a new predictor of antidepressant response to agomelatine? by C.S. Peretti; F. Levy; S. Mouchabac; S. Iglesias; G. Chouinard (S397-S398).

P.2.f.028 Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site, randomised controlled trial by J.W. Murrough; D.V. Iosifescu; L. Chang; R.K. Al Jurdi; C. Green; A. Perez; S.Z. Iqbal; S. Pillemer; A. Foulkes; S. Mathew (S411-S412).

P.2.f.023 Immediate cerebral blood flow changes induced by deep brain stimulation of subcallosal cingulate gyrus in treatment-resistant depression by M. Serra-Blasco; D. Puigdemont; J. De Diego; J. Molet; Y. Vives; E. Álvarez; V. Pérez; M.J. Portella (S408-S409).

P.2.f.021 6 months remission predictors of major depressive episode: data from the D-EXTENSION study by P. Courtet; I. Jaussent; G. Vaiva; E. Corruble; P.M. Llorca; F. Bayle; P. Gorwood (S407).

P.7.b.014 The association between the NR3C1 gene polymorphism and anorexia nervosa or stressful life events by M. Dmitrzak-Weglarz; A. Slopien; A. Szczepankiewicz; M. Tyszkiewicz-Nwafor; J. Hauser (S594).

P.7.b.015 Comparison between a familial versus a clinical high risk approach to the study of psychosis risk in adolescence by D. Ilzarbe; G. Sugranyes; I. Baeza; E. De la Serna; S. Romero; V. Sanchez-Gistau; M. Dolz; J. Castro-Fornieles (S594-S595).

P.7.b.016 Connectomic disturbances in ADHD combined versus predominantly inattentive type by S. Hong; A. Zalesky; A. Fornito; S. Park; Y. Yang; M. Park; M. Shin; B. Kim; S. Cho; J. Kim (S595-S596).

P.7.b.012 A scale for the assessment of hyperfocusing in attention deficit and hyperactivity disorder by E. Ozel-Kizil; H. Demirbas; G. Bastug; S. Kirici; E. Tathan; N. Kasmer; B. Baskak (S593).

P.7.b.011 First episode psychosis during adolescence: clinical and therapeutic differences from adulthood onset by M. García; D. Ilzarbe; S. Mansilla; A. Pérez; M. Fábrega; E. Parellada; G. Sugranyes; I. Baeza (S592-S593).

P.7.b.007 Stress responses in adults with attention-deficit and hyperactivity disorder (ADHD): gender differences by J.A. Ramos-Quiroga; G. Palomar; M. Corominas; R. Ferrer; R. Catalan; A. Real; M. Nogueira; M. Casas (S589-S590).

P.7.b.006 Connection between genetic variations of homocysteine metabolism and progression of schizophrenia by L. Kevere; S. Purvina; D. Bauze; M. Zeibarts; L. Piekuse; I. Purvins (S589).

P.7.b.008 Reduced serotonin transporter binding in adult ADHD investigated by PET and [11C]DASB by G. Kranz; M. Mitterhauser; A. Kutzelnigg; A. Hahn; D. Haeusler; A. Hoeflich; T. Vanicek; W. Wadsak; S. Kasper; R. Lanzenberger (S590-S591).

P.7.b.009 Distinct resting state functional connectivity correlates for specific dimensions of adolescent psychopathy by L.E. Pape; M.D. Cohn; L. Schmaal; W. Van den Brink; T.A.H. Doreleijers; D.J. Veltman; A. Popma (S591).

P.7.b.010 Ascertainment source and clinical correlates of autism spectrum disorders (ASD): a comparative study of ASD youth attending a specialty and a general psychiatry clinic by G. Joshi; J. Wozniak; C. Petty; R. Fried; M. Galdo; K. McDermott; C. Epstein; R. Walker; L.K. Feinberg; J. Biederman (S591-S592).

P.7.b.019 A new computational approach, mGWAS, identifies a novel drug target for autism by B. Bigio; V. Sonakya; M.K. Tonn; C. Nasca; K.M. Wittkowski (S597).

P.7.d.009 Methylphenidate hydrochloride modified release improved inattention and hyperactivity/impulsivity scores in adult ADHD patients by M. Huss; Y. Ginsberg; T. Tvedten; T. Arngrim; M. Greenbaum; A. Philipsen; K. Carter; C.W. Chen; P. Gandhi; V. Kumar (S604-S605).

P.7.d.008 Efficacy of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with ADHD: head-to-head responder analyses by E. Cardo; D. Coghill; P. Nagy; B. Adeyi; C. Anderson; B. Caballero; N. Higgins; P. Hodgkins; R. Civil; R.W. Dittmann (S603-S604).

P.7.d.010 Growth on stimulant medication: effects in children with ADHD by S. Carucci; T. Usala; F. Granitzio; C. Balia; D. Coghill; A. Zuddas (S605).

P.7.d.012 Paliperidone palmitate long-acting injection in adolescents: report of two cases by M. Fabrega Ribera; S. Garcia Chulbi; G. Sugranyes Ernest; I. Baeza Pertegaz (S606-S607).

P.7.d.007 Differences between responders and not responders treated with fluoxetine in a sample of adolescents by A. Blazquez; M.T. Plana; S. Mas; J.A. Arnaiz; A. Lafuente; L. Lázaro (S603).

P.7.d.002 Impact of previous ADHD medication on the efficacy of lisdexamfetamine dimesylate in the treatment of ADHD: post hoc analyses by D. Coghill; T. Banaschewski; M. Lecendreux; C. Soutullo; A. Zuddas; S. Sorooshian; B. Adeyi; L. Squires; R. Civil (S599-S600).

P.7.d.001 Health-related quality of life outcomes in a long-term study of lisdexamfetamine dimesylate in children and adolescents with ADHD by D. Coghill; T. Banaschewski; A. Zuddas; M. Johnson; P. Hodgkins; B. Adeyi; L. Squires; R. Civil (S598-S599).

P.7.d.005 Methylphenidate hydrochloride modified release led to a beneficial impact on family-, work- and social life in adult ADHD patients by M. Huss; Y. Ginsberg; T. Tvedten; T. Arngrim; M. Greenbaum; A. Philipsen; K. Carter; C.W. Chen; P. Gandhi; V. Kumar (S601-S602).

P.7.b.005 The association between gene polymorphisms and visual-spatial functions and organisation of graphomotor actions in ADHD patients by A. Slopien; A.R. Borkowska; M. Dmitrzak-Weglarz; A. Szczepankiewicz; N. Pytlinska; R. Komorowska-Pietrzykowska; F. Rybakowski; A. Rajewski; T. Wolanczyk; J. Hauser (S588-S589).

P.7.b.004 Influence of duration of untreated psychosis (DUP) on functional outcome in youth with first episode psychosis: a 2-year longitudinal study by A. Del Rey-Mejias; D. Fraguas; J. Castro-Fornieles; S. Otero; A. Gonzalez-Pinto; L. Pina-Camacho; C.M. Diaz-Caneja; C. Arango; I. Baeza; M. Parellada (S587-S588).

P.6.d.006 Aripiprazole plus topiramate in opioid-dependent patients with schizoaffective disorder: evidence from a pilot study by F. Cordova; A. Bruno; V.M. Romeo; G. Pandolfo; G. Scimeca; M.R.A. Muscatello; R.A. Zoccali (S577).

P.6.d.005 Differential effects of short- and long-term cocaine use on cortical volume, thickness and surface area by A.M. Kaag; C.L. Crunelle; W. Van den Brink; J. Homberg; L. Reneman (S576).

P.6.d.007 Fertilizers as a pathoplastic factor of psychosis by S. Marques; T. Reis; D. Barrocas; J. Góis (S577-S578).

P.6.e.002 Substance abuse patterns among university students: regional and gender differences by A. Unger; L. Brandt; A. Matznetter; C. Zachbauer; G. Fischer; R. Jagsch (S578-S579).

P.6.c.013 The effects of the new synthetic drugs mephedrone, methylone, naphyrone and 5,6-methylenedioxy-2-aminoindane (MDAI) in rats by T. Palenicek; F. Tyls; M. Fujakova; E. Lhotkova; L. Kaderabek; A. Kubesova (S572-S573).

P.6.c.012 Stereological characterisation of c-Fos expression in the nucleus accumbens and orbitofrontal cortex in mice after cocaine treatment by R. Santos; R. Frussa-Filho; A.V. Silva; C.L. Patti; E.A.V. Marinho; A.W. Hollais; T.S. Yokoyama; A.J. Oliveira-Lima; F. Talhati; B.M. Longo (S571-S572).

P.6.d.001 Inhibition-specific prefrontal connectivity after an acute dose of heroin by A. Schmidt; S. Borgwardt; O. Schmid; G.A. Wiesbeck; A. Riecher-Rössler; K. Bendfeldt; R. Smieskova; U.E. Lang; K. Rubia; M. Walter (S573-S574).

P.6.d.002 D3 receptor genotype (rs6280) impact on ventral striatal and amygdala volumes in abstinent cocaine dependent individuals by A. Verdejo-Garcia; L. Moreno-Lopez; N. Albein-Urios; B. Gutierrez; C. Soriano-Mas (S574-S575).

P.6.e.003 Modafinil induces the rapid-onset type of behavioral sensitization in mice by R. Wuo-Silva; D.F. Fukushiro; R. Santos; A.W. Hollais; S.B. Grapiglia; E. Mari-Kawamoto; L.B. Lopes-Silva; J.M. Costa; L.R.A. Bittencourt; R. Frussa-Filho (S579).

P.6.e.004 Glutamate and GABA alterations in the dorsal anterior cingulate cortex in nicotine dependence by M.H.J. Ter Mors-Schulte; A.E. Goudriaan; W. Van den Brink; R.W. Wiers; L. Schmaal (S580).

P.7.a.003 Affinity of alpha-MSH-reactive immunoglobulins in eating disorders and their effects on melanocortin 4 receptor signaling by N. Lucas; R. Legrand; K. Akkermann; N. Tennoune; P. Déchelotte; J. Harro; S.O. Fetissov (S585).

P.7.b.001 Clinical characteristics of depression among adolescent females: a cross-sectional study by M. Rabie; A.H. Khalil; M.F. Abd-El-Aziz; T.A. Abdou; A.H. El-Rasheed; W.M. Sabry (S585-S586).

P.7.b.003 Screening for autism in preterm children with birth weights less than 1500 g by I. Dudova; M. Kasparova; D. Markova; J. Lukaskova; S. Beranova; T. Urbanek; M. Hrdlicka (S587).

P.6.f.002 Clinical and therapeutic impact of substance abuse on patients with first-episode psychosis by A. Mhalla; I. Ben Mahmoud; L. Gassab; A. Mechri; L. Gaha (S581).

P.8.b.013 Suicide survivors with complicated grief (CG): do they differ from other kinds of bereaved individuals with CG? by C. Carmassi; E. Calderani; B. Pocai; S. Gemignani; M. Menichini; C. Manni; P. Scocco; L. Dell'Osso (S626-S627).

P.8.b.012 Sleep disorders in psychiatric patients: a review of the literature by A. Sarrigiannidis; D. Antoniadis; G. Garyfallos (S625-S626).

P.8.b.014 Relationship between spirituality/mysticism/psychoticism, PTSD and suicidality among 475 earthquake survivors by C. Carmassi; P. Stratta; E. Massimetti; M. Corsi; B. Pocai; S. Gemignani; A. Rossi; L. Dell'Osso (S627).

P.8.b.015 Validation of the Italian version of the Inventory of Complicated Grief (ICG) by C. Carmassi; I. Pergentini; E. Calderani; C. Manni; M. Menichini; S. Gemignani; B. Pocai; C. Bertelloni; L. Dell'Osso (S627-S628).

C.07.01 Neurobiology of alcohol dependence by A. Lingford-Hughes (S634).

Author Index (S639-S661).

Keyword Index (S663-S670).

C.11.02 The effect of symptoms on functioning and daily life by M. Lambert; P. McGuire; A. Schreiner; S. Galderisi (S636).

P.8.b.010 The quality of life of donors following living donor liver transplantation by A. El Missiry; R.E. Hashem; A.H. Khalil; A.M. Omar; M.S. El-Meteini; E.I. Abo El-Ela; M.A. Hamed (S624-S625).

P.7.e.003 Sleep in adolescents: association with emotional problems and suicidal ideation by P. Burón; S. Al-Halabí; E. Díaz-Mesa; M. Garrido; L. García-Álvarez; J.L. Rancaño; M. Casero; P.A.Z. García-Portilla; P.A. Sáiz; J. Bobes Burón; S. Al-Halabí; E. Díaz-Mesa; M. Garrido; L. García-Álvarez; J.L. Rancaño; M. Casero; P.A.Z. García-Portilla; P.A. Sáiz; J. Bobes (S613-S614).

P.7.f.001 Relationships between psychopathology and quality of life among adolescents: a structural equation modeling approach by D. Stevanovic; O. Atilola; Y.P. Singh Balhara; M. Avicenna; H. Kandemir; P. Vostanis; R. Knez; T. Franic; P. Petrov; Z. Vlaskalic (S614).

P.7.f.003 Neuropsychological characteristics of children and adolescents at high risk for psychosis and early onset first episode of psychosis by E. De la Serna; G. Sugranyes; I. Baeza; V. Sanchez-Gistau; S. Romero; O. Puig; C. Espelt; M. Dolz; J. Castro-Fornieles (S615-S616).

P.7.e.001 Risk behaviours and psychiatric symptoms among adolescents in European schools by V. Carli; C. Wasserman; M. Sarchiapone; C. Hoven; D. Wasserman (S612-S613).

P.7.d.020 Development and validation of a scale for children and adolescents to assess medication related suicidality by P. Santosh; I. Flamarique; D. Purper-Ouakil; A. Zuddas; C. Arango; A. Sutcliffe; H. Hanna; U. Schulze; J. Castro-Fornieles (S611-S612).

P.7.d.015 Therapeutic drug monitoring (TDM) of fluoxetine in children and adolescents by M. Koelch; A. Pfalzer; F. Keller; P. Plener; M. Gerlach (S608-S609).

P.7.d.017 Adolescents with schizophrenia spectrum disorders treated with electroconvulsive therapy or pharmacotherapy by I. Flamarique; J. Castro-Fornieles; E. De la Serna; A. Pons; M. Bernardo; I. Baeza (S609-S610).

P.7.d.018 Does pharmacological treatment affect brain neurometabolites in adolescents with obsessive–compulsive disorder? by A.E. Ortiz; A.G. Ortiz; C. Falcon; N. Bargalló; A. Morer; M.T. Plana; M.L. Láizaro (S610).

P.7.d.019 Treatment of cognitive deficits in adolescents with early-onset schizophrenia: a randomised controlled trial of cognitive remediation by O. Puig; R. Penadés; I. Baeza; E. De la Serna; V. Sánchez-Gistau; M. Bernardo; J. Castro-Fornieles (S611).

P.7.f.004 Adolescents presenting with designer drug intoxication in a pediatric toxicology department in Bucharest by C. Petrescu-Ghenea; I. Dobrescu; G.C. Anghel; V.G. Nitescu; D.A. Boghitoiu (S616-S617).

P.7.f.005 Development and initial validation of a suicidality scale for children and adolescents by I. Flamarique; J. Castro-Fornieles; D. Purper-Ouakil; A. Zuddas; C. Arango; A. Sutcliffe; H. Hanna; U. Schulze; P. Santosh (S617).

P.8.b.006 Mental distress and treatment interventions in myocardial infarction patients: gender differences by A. Juskiene; J. Juskenas; G. Kundrotas; A. Podlipskyte; V. Gelziniene; V. Jakumaite; R. Bunevicius (S622-S623).

P.8.b.007 Association between obesity indices and cognitive function in the elderly by S.I. Kim; H.J. Lee; K.W. Yun; Y.C. Kim; W.J. Lim; H.Y. Choi (S623).

P.8.b.004 Feasibility of centralised ratings for mental health safety screening in a dermatology trial by J.B.W. Williams; D. Popp; L.M. Price; J.A. Gross; D. Davis; D. Salvucci; M.J. Detke (S621-S622).

P.8.a.001 The effect of riboflavin (vitamin B2) on formalin-induced lumbar pain by A. Dondas; I. Chiriac; T. Alexa; A. Luca; D. Negru; C. Bohotin (S618-S619).

P.7.f.006 Gender profile of violent adolescents by E. Serfaty; A. Masautis; L. Florio (S617-S618).

P.8.a.002 Pharmacological effects and toxicity of newly synthesised peptidomimetic compounds by M. Novoselski; E. Encheva; D. Tsekova; R. Klissurov; S. Stoeva; L. Tancheva (S619).

P.8.b.002 Neuropsychological comorbidity in patients attended in internal medicine departments by J.A. Díaz Peromingo; J. Grandes Ibáñez; J.J. González Soler; M.F. García Suárez; J. Naveiro Soneira; I. Novo Veleiro; A. Fernández Rial; S. Molinos Castro; I. Íñiguez Vázquez; M.J. Domínguez Santalla (S620).

P.6.c.010 The efffect of agmatine in nucleus accumbens on morphine withdrawal signs in rats by H. Yananli; E. Sakalli; M. Caferova Demirkapu; B. Topkara; E. Mammadov; I.N.A. Dervishi; M. Caglar; O. Uslu; M. Beyatli (S570-S571).

P.4.e.003 The tumor supressor down-regulated in renal cell carcinoma 1 gene as a new link between stress, synaptic plasticity and behaviour by M. Masana; Y.A. Su; J. Dine; C. Liebl; K.V. Wagner; M. Eder; M.V. Schmidt; T. Rein; M.B. Müller (S526).

P.4.e.004 Involvement of μ opioid receptors in escape promoted in elevated T maze test by C. Biesdorf; C.M. Roncon; C.B. Almeida; H. Zangrossi; F.G. Graeff; E.A. Audi (S526-S527).

P.4.e.006 Orthorexia among Polish urban youth by M. Stochel; J.H. Joanna Hyrnik; I.J. Ireneusz Jelonek; J.Z. Jan Zejda; M.J.K. Malgorzata Janas-Kozik (S527-S528).

P.4.d.002 Effect of ziprasidone augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder by V. Currò; A. Bruno; G. Pandolfo; G. Scimeca; M.R.A. Muscatello; R.A. Zoccali (S524).

P.4.c.003 Identification of a significant role for the ventral hippocampus in neuropeptide S-elicited anxiolysis by I.A. Ionescu; J. Dine; J. Stepan; Y.C. Yen; F. Holsboer; R. Landgraf; M. Eder; U. Schmidt (S520).

P.4.c.005 Stress and corticosterone increase the readily releasable pool of vesicles in rat synaptosomes of prefrontal/frontal cortex by G. Treccani; L. Musazzi; C. Perego; M. Milanese; T. Bonifacino; J. Lamanna; A. Malgaroli; G. Racagni; G. Bonanno; M. Popoli (S521-S522).

P.4.f.006 Comparison of psoriasis patients with control groups in terms of psychiatric variables by O. Arisoy; C. Karakilic; M. Boztas; H. Kaya; A. Parlak (S534-S535).

P.4.f.004 Deep brain stimulation in obsessive–compulsive disorder induces striatal dopamine release by M. Figee; N.C.C. Vulink; G. Van Wingen; J. Booij; D. Denys (S533).

P.4.f.003 The cumulative effect of multiple childhood trauma on adult depression, PTSD and health-related quality of life by A. Agorastos; L.H. Aversa; J. Pittman; A. Goldsmith; C. Nievergelt; C.J. Hansen; D.G. Baker (S532-S533).

P.4.e.010 Anxiety in mothers of children with thalassemia by Z. Binbay; M. Solmaz; B. Turk Lal; S. Sagir (S530).

P.4.f.001 Alexithymia, emotion and quality of life in patients with atypical chest pain by J.H. Kim; S.H. Park; H.C. Lee; Y.M. Jae; S.H. Jang; J.H. Choi (S531).

P.4.c.002 Anxiolytic action of a new 5-HT2A antagonist RU-476 by D.V. Maltsev; D.S. Yakovlev; D.G. Matokhin; Y.V. Samsonik; A.A. Spasov; V.A. Anisimova (S519-S520).

P.4.c.001 Impact of alcohol withdrawal on working memory and brain chromatin remodeling in mice by D. Beracochea; G. Dominguez; M. Dagnas; N. Henkous; N. Mons (S519).

P.3.f.026 Could a simplified PANSS be more efficient? by G. Sachs; D. Daniel; J. Dries (S506-S507).

P.4.a.003 Negative and biased facial emotion recognition of social anxiety disorder patients by K.S. Oh; S.J. Cho; J.K. SaKong; E.J. Kim; S.W. Lim (S508-S509).

P.3.f.024 Increased slow waves in electroencephalogram (EEG) but not daytime sleepiness in schizophrenic patients during antipsychotic treatment by A. Wichniak; L. Okruszek; A. Wierzbicka; E. Waliniowska; K. Czasak; T. Jakubczyk; M. Jarema; W. Jernajczyk (S505-S506).

P.3.f.021 Dehydroepiandrosterone sulfate and cortisol levels in schizophrenia and bipolar patients by A. Gundogar; C. Korulsan; K.O. Karamustafalioglu (S503-S504).

P.3.f.023 Effect of COMT functional polymorphism on bias against disconfirmatory evidence in schizophrenia by M. Buonocore; M. Bosia; M. Bechi; R. Riccaboni; M. Piantanida; E. Smeraldi; R. Cavallaro (S505).

P.4.a.005 Reliability and validity of the Korean version of the combat exposure scale by T.Y. Kim; J.H. Choi; H.G. Chung; H.S. So (S509-S510).

P.4.a.006 Fractional amplitude of low-frequency fluctuations alterations in obsessive–compulsive disorder subtypes by A. Guinea-Izquierdo; I. Martínez-Zalacaín; C. López-Solà; R. Hernàndez-Ribas; M. Subirà; P. Alonso; C. Segalàs; J.M. Menchón; N. Cardoner; C. Soriano-Mas (S510-S511).

P.4.b.008 Structural covariance of striatal and limbic regions in obsessive–compulsive disorder by M. Subirà; O.A. Van den Heuvel; M. Cano; S. De Wit; M.Q. Hoexter; T. Nakamae; J.S. Kwon; D. Mataix-Cols; D.J. Stein; C. Soriano-Mas (S516).

P.4.b.010 Course of DSM-IV social anxiety disorders during pregnancy and postpartum by J. Martini; J. Petzoldt; J. Wittich; H.U. Wittchen (S517).

P.4.b.011 Death anxiety in elderly patients with generalized anxiety disorder by A. Kokurcan; E.T. Ozel-Kizil; S. Kirici (S518).

P.4.b.007 Relationship between altered cerebral activity and disease severity in obsessive–compulsive disorder: a resting state fMRI study by C.D. Daoun; C.G. Guillevin Carole; H.W. Hammi Wala; G.R. Guillevin Remy; N.J. Jaafari Nemathollah (S515-S516).

P.4.b.006 Objective versus subjective sleep efficiency in apnea and insomnia patients due to generalised anxiety disorder as compared with normals by S. Rosales-Rodriguez; B. Saletu; P. Anderer; G. Gruber; S. Parapatics; G. Dorffner; G.M. Saletu-Zyhlarz (S514-S515).

P.4.b.001 Symptom dimensions modulate amygdala activity in obsessive–compulsive disorder by E. Via; N. Cardoner; J. Pujol; P. Alonso; M. López-Solà; E. Real; O. Contreras-Rodríguez; J.M. Menchón; C. Soriano-Mas; B. Harrison (S511-S512).

P.4.b.003 Symptom dimensions and response to deep brain stimulation in obsessive–compulsive disorder by P. Alonso; C. Segalas; E. Real; C. López-Solà; G. Plans; M.A. Aparicio; J.M. Menchon (S512-S513).

P.4.b.004 Fear of dying and fear of guilt: panic disorder/agoraphobia comorbidity in obsessive–compulsive disorder by D.L.C. Costa; J.B. Diniz; Y.A. Ferrão; M.C. Rosario-Campos; E.C. Miguel; R.G. Shavitt; A.R. Torres; L.F. Fontenelle (S513).

P.4.b.005 Hypochondriasis, panic and obsessive–compulsive symptoms: genetic overlap in a twin-based population sample by C. Lopez-Sola; P. Alonso; L.F. Fontenelle; D. Cuadras; J.M. Menchón; B.J. Harrison (S514).

P.6.b.004 Efficacy of nalmefene as-needed in alcohol dependent patients with high drinking risk level: subgroup analysis of two studies by W. Van den Brink; H.J. Aubin; A. Bladström; L. Torup; A. Gual; K. Mann (S559-S560).

P.6.a.006 Deletion of cannabinoid CB2 receptor increases the reinforcing and motivational actions of ethanol by F. Navarrete Rueda; A. Ortega-Álvaro; A. Ternianov; A. Aracil-Fernández; M.S. García-Gutiérrez; J. Manzanares (S555-S556).

P.6.a.008 Neuropeptide S receptor gene variant and stressful life events: associations with alcohol use disorder and alcohol consumption by K. Laas; A. Reif; K. Akkermann; E. Kiive; K. Domschke; K.P. Lesch; T. Veidebaum; J. Harro (S557).

P.6.c.006 Cue-reactivity in prolonged, frequent cannabis use: a three year follow-up study by W.A.M. Vingerhoets; L. Koenders; J. Cousijn; T.A.M.J. Van Amelsvoort (S568).

P.6.c.005 Exposure to caffeine and sucrose changes locomotor behaviour, neurobiology and response to acute methamphetamine challenge by J.L. Franklin; M. Mirzaei; M.K. Sauer; T.A. Wearne; A.K. Goodchild; P.A. Haynes; J.L. Cornish (S567-S568).

P.6.c.007 Deletion or blockade of cannabinoid CB2 receptors modifies the reinforcing, motivational and physiological actions of nicotine in mice by F. Navarrete Rueda; M. Rodríguez-Arias; E. Martín-García; D. Navarro; M.S. García-Gutiérrez; A. Aracil-Fernández; P. Berbel; J. Miñarro; R. Maldonado; J. Manzanares (S568-S569).

P.6.c.008 Deep brain stimulation of the nucleus accumbens core affects heroin seeking and impulsivity in rats by M.C. Schippers; M. Gaastra; T. Mesman; Y. Van Mourik; D. Schetters; A.N.M. Schoffelmeer; T. Pattij; T.J. De Vries (S569-S570).

P.6.c.003 Environmental, genetic and epigenetic components in drug abuse and relapse to drug seeking by V. Carola; L. Lo Iacono; F. Visco Comandini; M.G. Alari; R. Furfaro; P. Caputo; S. Cabib; S. Puglisi-Allegra (S566).

P.6.b.011 Attentional bias and inhibitory behavioural changes in patients with alcohol dependence and bipolar disorders treated with aripiprazole by G. Rubio; R. Jurado-Barba; I. Martinez-Gras; G. Ponce; R. Rodriguez-Jimenez; I. Colado; J. Manzanares (S563-S564).

P.6.b.012 Management of affective disorders in alcohol-dependent patients by A. Bandati; A.O. Bandati; A. Albu (S564-S565).

P.6.c.001 Cannabis use is associated with biological markers of ageing in healthy volunteers by L. Scoriels; S. Theegala; M. Giro; S.E. Ozanne; K. Burling; P.B. Jones; E. Fernandez-Egea (S565).

P.6.c.002 A dipeptide analog of neurotensine (8–13) with mild analgesic activity significantly decreases opiate withdrawal signs in rats by M.A. Konstantinopolsky; I.V. Chernyakova; L.G. Kolik; V.S. Kudrin; P.M. Klodt; T.A. Gudasheva (S565-S566).

P.6.a.003 Spironolactone suppresses ethanol-seeking behavior and relapse in rats by V. Kashkin; E. Shekunova; Y. Bagrov; A. Bagrov (S553-S554).

P.5.b.006 Assessment of adiponectin and its isoforms in elderly women with late onset Alzheimer's disease and mild cognitive impairment by W. Bik; A. Baranowska-Bik; E. Wolinska-Witort; M. Kalisz; M. Styczynska; M. Chodakowska-Zebrowska; A. Pfeffer-Baczuk; M. Barcikowska; B. Baranowska (S542-S543).

P.5.b.008 Are there differential neuropsychological profiles in mild cognitive impairment patients with depressive symptoms? by M. Signorelli; E. Aguglia; F. Caraci; S. Castellano; S. Di Nuovo; A. Ullo (S544).

P.5.a.006 The effect of intracerebroventricular administration of (25–35)-β-amyloid fragment on EEG and cognition in the rat – a pilot study by L. Kaderabek; T. Palenicek; E. Lhotkova; F. Tyls; A. Kubesova; M. Fujakova; H. Tejkalova; V. Krajca (S538).

P.5.a.008 Effects of clinically approved, pro-cognitive pharmacological agents on electroencephalography in Alzheimer's disease-model mice by J. Kelley; L. Raeymaekers; A. Ahnaou; C. Babiloni; C. Czech; S. Dix; J.C. Richardson; E. Schenker; X. Langlois; W. Drinkenburg (S539).

P.5.b.001 Clinical characteristics and cognitive functions of late-onset psychoses: a case–control study by S. ElGhonemy; H. Sadek; R. Bassim; M. Soltan; D. El Serfei (S540).

P.5.b.002 Association between sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples by S. Porcelli; R. Salfi; A. Politis; A.R. Atti; D. Albani; L. Lia; G.N. Papadimitriou; D. De Ronchi; A. Serretti (S540-S541).

P.5.c.002 Nanoparticles as disease-modifying mediators for brain therapy: focus on Huntington's disease by B.M.D.C. Godinho; J.R. Ogier; R. Darcy; C.M. O'Driscoll; J.F. Cryan (S545).

P.5.f.002 Consensus and variations in opinions on delirium care: a survey of the European Delirium Association by D. Meagher; A. Morandi; D. Davis; J. Taylor; G. Bellelli; B. Olofsson; S. Kreisel (S551-S552).

P.6.a.001 Ghrelin and steroid hormones in serum of chronically alcoholised rats by P. Khokhlov; E.R. Bychkov; A.A. Lebedev; P.D. Shabanov (S552-S553).

P.5.d.007 Vivid dreams, hallucinations and psychosis in Guillain-Barre syndrome – case presentation by C. Crisan; I. Miclutia; O. Vanta; L. Perju-Dumbrava (S549-S550).

P.5.d.002 Cannabidiol add-on usual treatment improves the outcome of patients with Parkinson's disease by M.H.N. Chagas; V. Tumas; M. Penna-Pereira; M. Sobreira-Neto; E.T. Sobreira; A.L. Eckeli; J.E.C. Hallak; A.C. Dos Santos; J.A.S. Crippa; A.W. Zuardi (S546-S547).

P.5.d.004 Skin-picking heralding Parkinson's disease by K.Y. Chee; A.H. Evans; D. Velakoulis (S547-S548).

P.5.d.005 Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease by O.A. Van den Heuvel; C. Vriend; A.H. Nordbeck; J. Booij; Y.D. Van der Werf; T. Pattij; P. Voorn; P. Raijmakers; E. Van de Giessen; H.W. Berendse (S548-S549).

P.5.d.006 Dopaminergic dysregulation syndrome in Parkinson's disease: management in a psychiatric unit of a general hospital by A. Pérez Vigil; A. Fàbrega Ribera; R. Martin-Santos Laffon; A. Pons Villanueva (S549).

P.2.c.011 Overexpression of the homeobox Otx2 gene leads to spontaneous fluctuations in manic- and depressive-like behaviour by M. Jukic; A. Avin; M. Bar; T. Baron; K. Zega; O. Novikov; O. Kofman; G. Agam; C. Brodski (S360-S361).

P.1.b.001 Neural correlates of stressful life events at onset of obsessive-compulsive disorder by E. Real; C. Orfila; P. Alonso; C. Segalàs; J. Labad; M. Subirà; M. Pinillos; N. Cardoner; J.M. Menchón; C. Soriano-Mas (S174-S175).

P.1.a.026 Different regulation of endogenous neuropeptides gene expression in resistance to diet-induced obesity by M. Pucci; M.V. Micioni Di Bonaventura; R. Ciccocioppo; M. Maccarrone; C. Cifani; C. D'Addario (S174).

P.1.b.005 A diminished mismatch negativity response in misophonia, a potential marker for aggressive impulsivity by A.E. Schroder; A. Mazaheri; D. Petropoulos; V. Soto; R. Smolders; N.C.C. Vulink; D. Denys (S177).

P.1.a.024 Effect of a functional polymorphism of EAAT1 on cognitive impairment in bipolar disorder by G. Sferrazza Papa; S. Poletti; S. Dalla Spezia; C. Locatelli; C. Colombo; F. Benedetti (S173).

P.1.a.022 Role of phospholipases in response to treatment. Data from the STEP-BD study by M. Balestri; A. Drago; D. De Ronchi; A. Serretti (S172).

P.1.a.023 NRG1 and DISCI gene polymorphisms with respect to cognitive endophenotype in schizophrenia by D. Frydecka; A. Kiejna; M. Szewczuk-Boguslawska; A. Beszlej; E. Pawlak-Adamska; L. Karabon; A. Partyka; A. Tomkiewicz (S172-S173).

P.1.b.006 Auditory P300 in euthymic patients with bipolar disorder by N. Custal; E. Cerrillo; M. Veciana; J. Pedro; J. Montero; J.M. Crespo; J.M. Menchón (S177-S178).

P.1.b.007 Detailed anatomical mapping of ‘neuropeptide S’ expressing cell populations in the human brainstem by C. Adori; S. Barde; G.G. Kovacs; N. Bogdanovic; M. Palkovits; T. Hökfelt (S178).

P.1.e.004 Sex-hormone fluctuation triggers subclinical depressive symptoms and affects immune cell numbers in peripheral blood in healthy women by M. Heede; H. Søndergaard; A. Pinborg; K. Christensen; H. Ullum; F. Sellebjerg; G. Knudsen; V. Frokjaer (S183-S184).

P.1.e.003 Evidence for nongenomic modulation of synaptic plasticity by L-thyroxine in the hippocampus by S. Bitiktas; K. Sehrazat; B. Tan; H. Ornek; K. Ozdogan; N. Dursun; C. Suer (S183).

P.1.f.002 Suicide attempts and oxidative stress: is there a link? by M. Martin Subero; H. Odebrecht Vargas; S. Odebrecht Vargas Nunes; D. Sabbatini Barbosa; M. Mendonça Vargas; K. Venugopal; M. Berk; M. Maes (S185-S186).

P.1.e.002 Sex-dependent effects of chronic L-thyroxine treatment in the water maze by B. Tan; S. Bitiktas; S. Kavraal; B. Kandemir; I.A. Kurnaz; C. Suer (S182-S183).

P.1.b.009 Switching in bipolar disorder: the role of 3H-imipramine, 3H-paroxetine and 5-HT2 binding sites by E. Cerrillo; N. Custal; S. Morchón; P. Rosel; M. Urretavizcaya; J.M. Menchón; J.M. Crespo (S179-S180).

P.1.b.008 Impaired sleep continuity after intracerebroventricularly administered nesfatin-1 in rats by B. Horváth; S. Vas; K. Könczöl; C. Ádori; L. Kalmár; D. Pap; D. Kostyalik; R.S. Papp; Z.E. Tóth; G. Bagdy (S179).

P.1.b.010 Expectation of tactile events and body ownership in schizophrenia: pharmacological correlates by F. Ferri; M. Costantini; A. Salone; G. Di Iorio; A. Chiarelli; A. Merla; G. Martinotti; M. Di Giannantonio; V. Gallese (S180).

P.1.c.001 Cognitive impairment in children – candidate endophenotypes for schizophrenia by I. Sacuiu; A. Burlea-Ciubara; V. Chirita; R. Chirita (S180-S181).

P.1.a.017 S-Adenosyl-methionine impairs forced swimming-induced behavioural immobility by inhibiting gene expression in dentate gyrus neurons by E.A. Saunderson; A.F. Trollope; M. Gutièrrez-Mecinas; A.A. Shaikh; H. Spiers; J. Mill; J.M.H.M. Reul (S169).

P.1.a.001 Monoamine oxidase A DNA hypomethylation predicts impaired treatment response in depression by K. Domschke; N. Tidow; K. Schwarte; J. Deckert; V. Arolt; P. Zwanzger; B.T. Baune (S159).

P.1.a.002 Associations between ARLTL markers and symptoms dimensions in bipolar affective disorder by M. Maciukiewicz; M. Dmitrzak-Weglarz; P.M. Czerski; A. Leszczynska-Rodziewicz; P. Kapelski; A. Szczepankiewicz; M. Skibinska; J. Pawlak; J. Hauser; W.M. Karlowski (S159-S160).

E.02.01 Cognitive behaviour therapy in psychosis by M. Van der Gaag; C. De Roos (S155).

E.02.02 Trauma treatment in patients with a psychosis by C. De Roos; P. Van der Gaag (S155).

E.03.01 Obesity: a treatable brain disease? by A. Gearhardt (S155-S156).

E.03.02 Obesity and the brain: how convincing is the addiction model? by H. Ziauddeen; I.S. Farooqi; P.C. Fletcher (S156).

P.1.a.003 TNF-alpha −308 G>A polymorphism is associated with suicide attempt in major depressive disorder by Y.K. Kim; J.P. Hong; K.S. Na; S.W. Han; B.H. Lee; H.Y. Jung (S160-S161).

P.1.a.004 The identification of Ptpn1 in hippocampal modulation of food anticipatory behavior by E. Kostrzewa; L.A.W. Verhagen; C. Gelegen; H.A. Van Lith; D.A. Collier; M. Mitsogiannis; E. De Vries; M. Van Gestel; R.A. Adan; M.J.H. Kas (S161).

P.1.a.012 Association between dysbindin gene and cerebral structures in a Spanish population by N. Varela; I. Mata; R. Ayesa; R. Roiz; B. Crespo-Facorro (S166).

P.1.a.014 Expression studies of GTP-binding protein D-Ras2 (DIRAS2), a candidate gene for ADHD by L. Weissflog; E.T. Landaas; A. Camphausen; K.P. Lesch; A. Reif (S167).

P.1.a.016 CHL1 gene: a new promising antidepressant response marker in major depression by C. Fabbri; D. Gurwitz; J. Stingl; C. Crisafulli; E. Spina; S. Kasper; J. Zohar; D. Souery; J. Mendlewicz; A. Serretti (S168-S169).

P.1.a.010 DNA methylation of the BDNF gene in schizophrenia by L. Carlberg; J. Scheibelreiter; M.R. Hassler; M. Schloeglhofer; M. Schmoeger; B. Ludwig; S. Kasper; H. Aschauer; G. Egger; A. Schosser (S165).

P.1.a.007 FKBP5 single markers and haplotypes predispose to major depressive disorder in Polish patients by B. Narozna; A. Szczepankiewicz; A. Leszczynska-Rodziewicz; J. Pawlak; M. Wilkosc; A. Rajewska-Rager; M. Maciukiewicz; J. Twarowska-Hauser (S163).

P.1.a.008 Increased DNA methylation of the prodynorphin gene promoter in peripheral blood mononuclear cells from patients with bipolar disorder by A. Di Francesco; B. Dell'Osso; M.C. Palazzo; B. Benatti; D. Galimberti; B. Arosio; A.C. Altamura; M. Maccarrone; C. D'Addario (S163-S164).

P.1.a.009 The SNP rs2883187 of brain-derived neurotrophic factor (BDNF) is associated with symptom severity in obsessive-compulsive disorder by R. Tukel; B. Ozata; N. Ozturk; B. Aslantas Ertekin; E. Ertekin; G. Saruhan Direskeneli (S164-S165).

P.1.f.003 Pro-inflammatory cytokines induce anhedonia in mice and increase monoamine transporter activity in the nucleus accumbens by F. Van Heesch; J. Prins; K.G.C. Westphal; G.A.H. Korte-Bouws; B. Olivier; A.D. Kraneveld; S.M. Korte (S186).

P.1.g.035 The role of P-glycoprotein in central sedative effects of H1-antihistamines by S. Conen; E.L. Theunissen; A. Vermeeren; M. Mehta; J.G. Ramaekers (S209).

P.1.g.034 Effect of lisdexamfetamine in a rat model of binge-eating disorder by D. Heal; S. Vickers; D. Hackett; P. Hutson (S208-S209).

P.1.g.036 Role of cannabinoid CB1 receptor in the regulation of aggressive social behaviour by M. Rodríguez-Arias; F. Navarrete Rueda; M. Daza-Losada; D. Navarro; M.A. Aguilar; P. Berbel; J. Miñarro; J. Manzanares (S209-S210).

P.1.g.037 Methylphenidate, but not antipsychotics, improves prepulse inhibition deficits displayed by CB1 knockout mice by F. Navarrete Rueda; A. Ortega-Álvaro; A. Aracil-Fernández; A. Ternianov; J. Manzanares (S210).

P.1.g.039 Behavioural and neurochemical evidence for implication of the cannabinoid CB1 receptor in the effects of d-amphetamine by A. Polissidis; A. Galanopoulos; O. Chouliara; Z. Papadopoulou-Daifoti; K. Antoniou (S211-S212).

P.1.g.028 Vilazodone exhibits a favorable sexual profile in male rats by R.S. Oosting; J. Chan; B. Olivier; P. Banerjee (S205).

P.1.g.027 Antidepressant-like effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline in a reserpine model of depression in rat by J. Michaluk; E. Mozdzen; A. Wasik; I. Romanska; L. Antkiewicz-Michaluk (S204-S205).

P.1.g.030 Evaluation of trazodone sleep–wake profile in the rat by B. Garrone; L. Durando; E. Esneault; D. Virley; S. Tongiani (S206).

P.1.g.031 Functional coupling of group II metabotropic glutamate receptors to Gα-proteins in postmortem frontal cortex of schizophrenic subjects by A. García-Bea; P. Miranda-Azpiazu; R. Díez-Alarcia; A.M. Gabilondo; B. Morentín; J. González-Maeso; J.J. Meana (S206-S207).

P.1.g.040 Role of cannabinoid CB1 receptors in modulation of dopamine output in the prefrontal cortex associated with food restriction in rats by V. Licheri; G. Talani; L. Dazzi; F. Biggio; C. Utzeri; V. Lallai; S. Lutzu; G. Biggio; E. Sanna (S212).

P.1.g.041 Cannabinoid-induced actomyosin contractility leads both to rapid and lasting changes in neuronal morphology by A. Roland; D. Carrel; A. Ricobaraza; B.M. Jordan; F. Rico; A. Simon; M. Humbert-Claude; S. Scheuring; Z. Lenkei (S213).

P.1.g.050 Antidepressant-like effect of celecoxib and piroxicam in rat models of depression by M. Vital; R.M. Santiago; J.K. Barbiero; B.J. Martynhak; S.L. Boschen; L.M. Silva; M.F. Werner; C. Da Cunha; M.M.S. Lima; R. Andreatini (S218).

P.1.g.049 Does the peroxisome proliferator-activated receptor (PPAR)-alpha agonist fenofibrate protect against dopaminergic neuronal death in a rat model of Parkinson's disease? by J.K. Barbiero; R.M. Santiago; F.S. Tonin; S. Boschen; L. Motta; M.F. Werner; C. Da Cunha; M.M.S. Lima; M. Vital (S217-S218).

P.1.g.051 Neuroprotective effect of ibuprofen in a rat model of Parkinsonism induced by prolonged administration with rotenone by T. Zaminelli; R.W. Gradowski; T.B. Bassani; J.K. Barbiero; R.M. Santiago; M. Vital (S219).

P.1.g.052 Understanding blood-brain barrier penetration and link to target engagement by V. Sinha; I. Loryan; P. De Boer; X. Langlois; C. Mackie; A. Van Peer; W. Drinkenburg; A. Vermeulen; D. Heald; M. Hammarlund-Udenaes (S219-S220).

P.1.g.053 Role of acetylcholine-mediated neurotransmission within nucleus raphe magnus in the post-ictal antinociception by R.C. De Oliveira; T. Paschoalin-Maurin; R. De Oliveira; N.C. Coimbra (S220).

P.1.g.048 Antidepressant-like effect of melatonin in a rat model of Parkinson's disease induced by rotenone by T.B. Bassani; R.W. Gradowski; T. Zaminelli; J.K. Barbiero; R.M. Santiago; M. Vital (S217).

P.1.g.043 Psychopharmacological treatment in heart transplantation candidates by R. Sánchez González; J.M. Peri; E. Baillés; A. Bastidas; F. Pérez-Villa; A. Bulbena; L. Pintor Pérez (S214).

P.1.g.044 Effects of pharmacologically induced sex-hormone fluctuations on emotional processing of faces in healthy women by S. Henningsson; K.H. Madsen; A. Pinborg; M. Heede; G.M. Knudsen; H.R. Siebner; V.G. Frokjaer (S214-S215).

P.1.g.045 Neuroprotective effect of the monoacylglycerol lipase inhibitor JZL184 in a parkinsonian mouse model by M. Celorrio; D. Fernández-Suárez; R. Franco; M.S. Aymerich (S215).

P.1.g.026 Neuroprotective tetrahydroisoquinoline alkaloids have antidepressant-like effects in the clonidine model of depression by L. Antkiewicz-Michaluk; I. Romanska Irena; A. Wasik; E. Mozdzen; J. Michaluk (S203-S204).

P.1.g.025 N-Acetyl cysteine as a potential tobacco use cessation agent in bipolar disorder and schizophrenia by M. Rapado-Castro; S. Dodd; O. Dean; Z.X. On; A.I. Bush; M. Berk (S203).

P.1.g.008 Sub-anesthetic ketamine modulates intrinsic BOLD connectivity between the hippocampus and the prefrontal cortex in the rat by N. Gass; A.J. Schwarz; A. Sartorius; E. Schenker; C. Risterucci; M. Spedding; L. Zheng; A. Meyer-Lindenberg; W. Weber-Fahr (S192-S193).

P.1.g.009 Serotonin transporter binding is increased by a gonadotropin-releasing hormone agonist in female rats by A. Overgaard; M.E.K. Lie; C.V. Jorgensen; J.D. Mikkelsen; G.M. Knudsen; V.G. Frokjaer (S193-S194).

P.1.g.004 Influence of ABCB-1 genotype on spontaneous sleep and sleep-EEG changes after escitalopram in healthy volunteers by A. Steiger; M. Kluge; M. Dresler; B. Wollweber; A. Yassouridis; M. Uhr (S190-S191).

P.1.f.006 Functional reorganisation of the mesolimbic system after its terminal area destruction influences blood T lymphocytes and their subsets by K. Plucinska; B. Grembecka; W. Glac; D. Myslinska; G. Jerzemowska; P. Badtke; D. Wrona (S188).

P.1.g.001 Effects of carvedilol on the social behavior of rats submitted to an animal model of mania by B.M.M. Ribeiro; G.C. Souza; A.I.G. Queiroz; J.A.S. Gomes; L.M. Cavalcante; M.J.S. Machado; M.M. Araujo; R.C. Cordeiro; A.F. Carvalho; D.S. Macedo (S189).

P.1.g.011 Effect of chronic fluoxetine treatment on subthalamic nucleus and catalepsy in the rat by L. Ugedo; T. Morera-Herreras; J.A. Ruiz-Ortega; I. Vidaurrazaga; C. Miguelez; A. Aristieta (S194-S195).

P.1.g.022 Hallucinogenic and non-hallucinogenic 5-HT2A receptor agonists induce distinct patterns of G protein coupling in postmortem human brain by P. Miranda-Azpiazu; R. Díez-Alarcia; A. García-Bea; J. González-Maeso; B. Morentín; J.J. Meana (S201).

P.1.g.024 Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia by A. Maat; W. Cahn; H.J. Gijsman; J.E. Hovens; R.S. Kahn; A. Aleman (S202-S203).

P.1.g.016 Effects of tianeptine on mammalian target of rapamycin (mTOR) signaling in rat hippocampal neurons by M.K. Seo; C.H. Lee; H.Y. Cho; S.W. Park; B.J. Lee; J.G. Lee; Y.H. Kim (S197-S198).

P.1.g.017 BDNF-TrkB mediation of mechanical hyperalgesia in a rat model of chronic neuropathic pain by S. M'Dahoma; S. Barthélémy; B. Michot; F. Viguier; C. Tromilin; S. Pezet; M. Hamon; S. Bourgoin (S198).

S.07.08 Using Positron Emission Tomography to investigate microglial activation in alcohol dependence: preliminary findings by N.J. Kalk; Q. Guo; D.R. Owen; A. Waldman; K. Dar; R. Gunn; D.J. Nutt; E.A. Rabiner; A.R. Lingford-Hughes (S122).

S.07.01 A proteomic and functional analysis reveals that 5-HT6 receptors modulate neuronal differentiation by recruitment of Cdk5 by F. Duhr; M. Séveno; C. Marmoury la Cour; D. Dupuis; M.J. Millan; J. Bockaert; P. Marin; S. Chaumont-Dubel (S120).

S.07.02 Role of trace amine-associated receptor 1 (TAAR1) in the modulation of dopaminergic system and cortico-striatal signalling by S. Espinoza; I. Sukhanov; G. Lignani; L. Medrihan; S. Maggi; G. Giannotti; F. Fumagalli; F. Benfenati; V. Tucci; R.R. Gainetdinov (S120).

S.12.01 Identification of a significant role for the ventral hippocampus in neuropeptide S-elicited anxiolysis by I.A. Ionescu; J. Dine; J. Stepan; Y.C. Yen; L. Herrmann; F. Holsboer; C.T. Wotjak; R. Landgraf; M. Eder; U. Schmidt (S128-S129).

S.12.03 Effect of early life experiences on brain structure and function: neurogenesis and decision making by M. Loi; S. Koricka; L. De Visser; M.J. Kas; P.J. Lucassen; M. Joels (S129).

S.12.04 Targeting postsynaptic density protein 95(PSD-95)/Discs large/Zonula occludens-1 (PDZ)-interactions of the glutamatergic synapse in animal models of depression by F. Freudenberg; V. Marx; V. Mack; L.E. Layer; M. Klugmann; P.H. Seeburg; R. Sprengel; T. Celikel (S129-S130).

S.11.01 Epigenetics in ageing and Alzheimer's disease by D. Van den Hove; L. Chouliaras; D. Mastroeni; P.D. Coleman; K.P. Lesch; H.W. Steinbusch; B.P. Rutten (S127).

S.09.03 The role of habit in obsessive-compulsive disorders: implications for pharmacotherapy by N.A. Fineberg; B.J. Sahakian; S.R. Chamberlain; C.M. Gillan; A.M. Apergis Schoute; S. Morein-Zamir; V. Voon; E. Bullmore; K. Jefferies; T.W. Robbins (S125).

S.06.03 Persistence of brain deficits in adult ADHD by A. Cubillo; K. Rubia (S119).

S.02.01 Alterations in default mode network connectivity during pain processing in borderline personality disorder by R. Kluetsch; C. Schmahl; I. Niedtfeld; M. Densmore; V. Calhoun; J. Daniels; A. Kraus; P. Ludaescher; M. Bohus; R. Lanius (S112).

S.02.02 Dopamine D2 and serotonin 5-HT1A receptors of the brain in processing of pain by A. Pertovaara; I.K. Martikainen; N. Hagelberg; J. Hirvonen; H. Scheinin; J. Hietala (S113).

PL.05.01 The future of molecular pharmacology and drug discovery in psychiatry by M. Caron; N.M. Urs; S.M. Peterson; J.C. Snyder (S108-S109).

S.02.04 Insular dysfunction and descending pain inhibition in anorexia nervosa by K.J. Bär; F. Beissner; G. Wagner (S113-S114).

S.04.02 Tau, axonal transport and Alzheimer's disease by E.M. Mandelkow; A. Sydow; K. Hochgräfe; Y. Kumar; H. Zempel; E. Mandelkow (S115-S116).

S.03.01 Alterations of the hippocampal-prefrontal pathway in schizophrenia: effect of antipsychotic drugs by M. Spedding; E. Schenker; B.P. Godsil; T.M. Jay; C. Sebban; S. Takillah; P.H. Faure; C. Siok; M. Hajos; J. Bastlund; K. Wicke; F. Artigas (S114).

S.12.05 Serotonin regulates hippocampal synaptic plasticity and object memory in mice by S. Fernandez; A. Gruart; J.M. Delgado; P. Gaspar (S130).

S.23.03 Imaging of the serotonin system by G.M. Knudsen (S145).

S.22.02 Intervention directed at emotion recognition in delinquent adolescents by S.H.M. Van Goozen; K.L. Bowen; K. Main (S143).

S.22.03 Neuroimaging of fear conditioning and reward/punishment anticipation in the persistence of antisocial behaviour by M.D. Cohn; A. Popma; W. Van den Brink; L.E. Pape; M. Kindt; L. Van Domburgh; T.A.H. Doreleijers; D.J. Veltman (S143-S144).

S.22.04 Brain-regulation learning in criminal psychopaths by L. Konicar; R. Veit; U. Strehl; N. Birbaumer (S144).

S.27.02 Tauopathy and mitochondria by A. Eckert (S151).

S.27.01 Mitochondria and Aβ metabolism by M. Ankarcrona (S150-S151).

S.28.01 GABAergic interneuron synaptic dysfunction and schizophrenia by I. Del Pino; C. García-Frigola; E. Alvarez; M. Martínez de Lagran; G. Ciceri; M. Dierssen; S. Canals; O. Marín; B. Rico (S152).

S.26.03 Dopaminergic dysfunction and reward learning in bulimia nervosa by G. Hasler; P. Homan; S. Grob; U. Schnyder; G. Milos; H. Moeregeli (S150).

S.14.02 Testing the effect of alcohol intake and naltrexone treatment on brain networks using combined rsMRI/MEMRI in rats by S. Canals; A. Moreno; V. Pallarés; J. Pacheco-Torres; D. Moratal; F. De la Cruz; B. Fernández; R. Ciccocioppo; P. Hyytiä; W. Sommer (S134).

S.14.04 Testing the effect of modafinil on functional connectivity and impulsivity in alcohol dependent patients by L. Schmaal; A.E. Goudriaan; L. Joos; G. Dom; W. Van den Brink; D.J. Veltman (S134-S135).

S.14.01 Can brain connectivity predict outcome in alcoholism treatment: the TRANSALC project by W.H. Sommer; W. Weber-Fahr; S. Vollstädt-Klein; M.W. Meinhardt; M. Brown; P. Hyytä; S. Canals; K. Mann; D. Hermann (S133-S134).

S.13.04 Nicotinic alpha7 treatments for improving cognitive symptoms – proof of concept and further developments by D. Hilt; M. Gawryl; N. Dgetluck; G. Koenig; H.J. Moebius; H. Meltzer (S133).

S.12.08 Lithium-regulated genes in peripheral cell models of bipolar-affective patients by S. Kittel-Schneider; M. Hilscher; S. Schreck; R. Schwarz; C.J. Scholz; L. Weißflog; A. Reif (S131).

S.12.07 Role of 5-HT1A/5-HT2A receptors interaction in the severity of depression and antidepressant response by G. Quesseveur; A.C. Petit; F. Gressier; R. Colle; D.J. David; A.M. Gardier; C. Verstuyft; C. Sanchez; E. Corruble; B.P. Guiard (S131).

S.18.04 Influence of reproductive hormones on mood and anxiety in women: premenstrual dysphoric disorders by I. Sundström Poromaa; M. Gingnell; E. Bannbers; J. Wikström; J. Engman; M. Fredrikson (S139).

S.18.03 Sex-hormone regulation and neuroimaging-markers of serotonergic neurotransmission and brain connectivity by V.G. Frokjaer; A. Pinborg; M. Heede; S. Henningson; C. Svarer; K.K. Holst; G.M. Knudsen (S139).

S.18.02 Sex hormonal fluctuations and the female human brain by J. Sacher; J. Hoyer; K. Arelin; K. Mueller; A. Villringer (S138).

S.16.04 A non convulsant alpha5 selective GABA-A inverse agonist restores cognitive deficits in a mouse model of Down syndrome by B. Delatour; J. Braudeau; A. Duchon; L. Dauphinot; R.H. Dodd; Y. Hérault; M.C. Potier (S136-S137).

S.17.03 The nucleus accumbens: a safe and well tolerated target for DBS in treatment resistant depression by B. Millet; F. Le Jeune; N. Jaafari; M. Polosan; B. Giordana; F. Naudet; J.M. Reymann; P. Fossati; P. Cornu (S137-S138).

S.17.04 New targets for deep brain stimulation in addiction by J. Luigjes; W. Van den Brink; D. Denys (S138).

P.1.g.054 Gene-expression imaging by N-methyl-D-aspartate receptor antagonists: implications for dopamine–glutamate interplay in psychosis by E.F. Buonaguro; F. Marmo; C. Sarappa; A. Eramo; C. Tomasetti; F. Iasevoli; A. De Bartolomeis (S220-S221).

P.2.a.010 Serotonin transporter-siRNA rapidly exerts antidepressant effects following internalisation into serotonergic neurons by A. Ferres-Coy; F. Pilar-Cuellar; R. Vidal; M. Galofré; V. Paz; L. Campa; A. Montefeltro; E.M. Valdizan; F. Artigas; A. Bortolozzi (S313-S314).

P.2.a.011 Chronic mild stress-induced behavioural and epigenetic changes in mice – prevention by agomelatine treatment by F. Boulle; R. Massart; L. Zaidan; S. Marday; C. Gabriel; E. Mocaër; M. Hamon; L. Lanfumey (S314-S315).

P.2.a.014 The role of the GPR39-Zn2+-sensing receptor in the pathomechanism of depression by K. Mlyniec; U. Doboszewska; B. Budziszewska; G. Nowak (S316).

P.2.a.013 Antidepressant treatment and prefrontal cortex-hippocampus connection inhibition: communicating vessels? by V. Kafetzopoulos; N. Kokras; A. Vassalou; K. Antoniou; Z. Papadopoulou-Daifoti; C. Dalla (S315-S316).

P.2.a.007 Early and time-dependent modulation of rat hippocampal miRNome during treatment with agomelatine by D. Tardito; M. Seguini; D. Corrada; I. Merelli; A. Mallei; L. Milanesi; G.A. Racagni; M. Popoli (S312).

P.2.a.003 Antidepressant-like effect of NOP receptor antagonist BAN ORL 24 by A. Twardowschy; R. Andreatini; N.C. Coimbra (S309-S310).

P.2.a.002 Stressful experience during peri-adolescent period induces depression-like phenotype in adult mouse by L. Lo Iacono; F. Visco Comandini; S. Puglisi-Allegra; V. Carola (S308-S309).

P.2.a.004 Study of the effect of personality in daily life experiences by E. Komulainen; K. Meskanen; P. Jylhä; J. Lahti; E. Isometsä; J. Ekelund (S310).

P.2.a.005 Antidepressant-like effect of 1,2,3,4-tetrahydroisoquinoline in forced swim test in comparison to citalopram by E. Mozdzen; J. Michaluk; A. Wasik; I. Romanska; L. Antkiewicz-Michaluk (S310-S311).

P.2.a.016 Electrode implantation produces an early response to deep brain stimulation in depression: potential role of regional neuroinflammation by L. Perez-Caballero; R. Perez-Egea; D. Puigdemont; C. Romero-Grimaldi; J. Molet; J.R. Caso; J.A. Mico; V. Pérez; J.C. Leza; E. Berrocoso (S317-S318).

P.2.b.010 Genetic predictor of antidepressant response for major depressive disorder: a genome-wide association study and pathway analysis by W. Nakano; D. Mehta; M. Ising; H. Pfister; D. Czamara; F. Holsboer; S. Lucae; A. Erhardt-Lehmann; E.B. Binder (S324-S325).

P.2.b.001 Cognitive functioning after deep brain stimulation in subcallosal cingulate gyrus for treatment-resistant depression by M. Serra-Blasco; S. De Vita; M. Rivas; J. De Diego; D. Puigdemont; A. Martin-Blanco; E. Alvarez; V. Pérez; M.J. Portella (S318-S319).

P.2.a.017 Effects of hypergravity on serotonin-related gene expression in the mouse brain by M. Yoshioka; S. Inubushi; T. Ochiai; M. Miyamoto; Y. Ohira; H. Ohta (S318).

P.2.b.002 Comparative analysis of agomelatine and trazodone in late-onset major depression by D. Vasile; O. Vasiliu; C. Tudor; A.G. Mangalagiu; O. Magazin; G.A. Sopterean; R.E. Bratu (S319-S320).

P.2.b.003 Mirtazapine versus sertraline in the treatment of post-psychotic depression by D. Vasile; O. Vasiliu; A.G. Mangalagiu; G.A. Sopterean; R.E. Bratu (S320).

P.2.b.004 Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: tianeptine versus escitalopram by H.J. Jeon; J.M. Woo; S.H. Lee; E.J. Kim; S.H. Chung; J.H. Ha; M. Fava; D. Mischoulon; J.H. Kim; B.H. Yu (S320-S321).

P.2.a.001 Social interaction with a rhythmic rat prevents depressive-like behaviour induced by constant light by B.J. Martynhak; L.K.S. Kanazawa; G.M. Nascimento; R. Andreatini (S308).

P.1.k.015 Bayesian tools for optimizing adaptive clinical trials by C. Siu; C. Brambilla; F. Ruggeri (S307-S308).

P.1.j.026 Cognitive deficits caused by hippocampal disinhibition: attentional and memory deficits by S. McGarrity; K.C. Kevin; R. Mason; M.A. Pezze; T. Bast (S296-S297).

P.1.j.027 Insight into illness and subjective quality-of-life assessment in chronic schizophrenia by C. Siu; O. Agid; M. Waye; C. Brambilla; G. Remington; P. Harvey (S297).

P.1.j.024 Theory of mind deficit in bipolar patients with subsyndromal illness by M. Simon; R. Herold; A.S. Hajnal; E. Varga; S. Fekete; T. Tényi (S295-S296).

P.1.j.023 Social cognition and executive deficits in bipolar disorder and schizophrenia: preliminary data by M. Cigliobianco; E. Caletti; P. Grillo; A. Caldiroli; M. Serati; G. Orsenigo; E. Zugno; R.A. Paoli; S. Zago; A.C. Altamura (S295).

P.1.j.019 Cognitive deficit in myotonic dystrophy type 1 by Y.G. Park; S.M. Kim; Y.C. Choi (S292-S293).

P.1.j.018 Deletion of cannabinoid-2 receptors induces memory impairment associated with synaptic plasticity alterations by M. García-Gutiérrez; A. Ortega-Alvaro; A. Busquets; J.M. Péirez-Ortiz; L. Caltana; M.J. Ricatti; A. Brusco; R. Maldonado; J. Manzanares (S291-S292).

P.1.j.020 Specific white-matter connectivity alterations in posttraumatic-stress disorder patients: correlation to associative memory deficits by R. Saar-Ashkenazy; J. Cohen; J. Guez; C. Gasho; I. Shelef; A. Friedman; H. Shalev (S293).

P.1.j.021 Cognitive abilities are changed in gamma-synuclein knockout mice by V. Kokhan; G. Van'kin; I. Shamakina (S293-S294).

P.1.j.022 A dopamine D1 agonist improved ketamineinduced spatial working memory dysfunction in common marmosets by T. Nakako; T. Murai; M. Ikejiri; T. Ishiyama; M. Taiji; K. Ikeda (S294).

P.1.k.001 Psychiatric disorders, violence and their relationship with substance abuse by J. León Caballero; M. Llobet Farré; D. Córcoles Martínez; M. Bellsola González; A. González Fresnero; M.T. Nascimento Osorio; M.A. Malagon Amor (S299).

P.1.k.010 Depression and anxiety in patients with Crohn's disease by L. Trikos; A. Jovanovic; D. Bojic; N.J. Jojic (S304).

P.1.k.008 Is Type A behavior pattern protective of diabetes complication? A study in 400 patients with diabetes by J. Chauvet-Gelinier; B. Verges; B. Trojak; E. Ponavoy; B. Bouillet; V. Meille; M. Benetti; M. Briki; I. Robin; B. Bonin (S303).

P.1.k.004 Sociodemographic and clinical characteristics of involuntary admissions in patients with schizophrenia and bipolar disorder by S.L. Romero Guillena; B.O. Plasencia Garcia de Diego; N. Casas Barquero; L. Muñoz García-Largo (S300-S301).

P.1.k.003 Somatisation and alexithymia in general medical practice by I. Natsov; G. Hranov; L.G. Hranov (S300).

P.1.k.005 Co-morbidity between epilepsy and severe psychiatric illness: a population-based study by O. Kapara; E. Feruchter; A. Reichenberg; R. Yoffe; O. Fono-Yetiv; I. Kreiss; M. Davidson; M. Weiser (S301-S302).

P.1.k.006 Impulse control disorders in elderly patients by L. Tamam; M. Bican; N. Keskin (S302).

P.1.k.007 Prevalence and related risk factors of suicidal ideation of adolescents in an urban area by S.J. Cho; T.H. Lee; Y.J. Lee; S.J. Kim; K.S. Oh (S302-S303).

P.2.b.054 Psychiatric induced disorders and quality of life of substance abusers with chronic hepatitis C under interferon-alpha treatment by J. Moreno; M. Udina; R. Navines; P. Castellvi; M. Torrens; R. Sola; R. Martín-Santos (S351).

P.2.b.048 Functional impairment in major depressive disorder: preliminary findings of the PERFORM study by D. Saragoussi; J.M. Haro; J.P. Boulenger; F.X. Lamy; S. Di Nicola; B. Rive (S347-S348).

P.2.b.043 Glucocorticoid receptors, serotonin and dopamine neurotransmission are associated with interferon-induced depression by M. Udina; R. Navinés; I. Grande; A.E. Nardi; K. Langohr; M. Gratacòs; E. Vieta; M. Valdés; R. Solà; R. Martín-Santos (S344-S345).

P.2.b.044 Serotonin transporter association between dorsal raphe and ventral striatum is diminished in major depression by A. Hahn; D. Haeusler; C. Kraus; A.S. Höflich; G.S. Kranz; P. Baldinger; M. Mitterhauser; W. Wadsak; S. Kasper; R. Lanzenberger (S345).

P.2.b.045 Treatment of major depression reduces arterial stiffness by N. Kokras; A.V. Kouzoupis; C. Papamichael; G.N. Papadimitriou; K.S. Stamatelopoulos (S345-S346).

P.2.c.005 Myricitrin, a PKC inhibitor, exerts antimanic-like effects in animal models by R. Andreatini; M. Pereira; I.P. Siba; M.G. Pizzolatti; A.R.S. Santos; A.P. Ruani (S357-S358).

P.2.c.004 Frontopolar inefficiency and anterior cingulate overactivation during working memory: early stage abnormalities in bipolar disorder by J.M. Goikolea; D. Dima; I. Torres; R. Landín-Romero; G. Delvecchio; M. Valentí; B. Amman; E. Pomarol-Clotet; E. Vieta; S. Frangou (S357).

P.2.c.006 The role of tetraspanin 8 in bipolar disorder by C. Schartner; C.J. Scholz; H. Weber; L. Weißflog; A. Reif (S358-S359).

P.2.c.008 Increased mitochondrial lipid peroxidation in depression bipolar episode by L. Jornada; A. Steckert; F. Scussel; G. Ferreira; E. Streck; P. Ferrari; B. Pfaffenseller; M. Costanzi; L. Czepielewski; J. Quevedo (S359-S360).

P.2.c.003 Subjective Well-being under Neuroleptic Scale in outpatients with bipolar disorder by S.L. Romero Guillena; F. Gotor; O. Santamaria (S356-S357).

P.2.b.057 Prevalence of depression in elderly patients with chronic physical illness by H. Lee; S. Hahn; S. Shim; Y. Kwon; H. Jeong (S353).

P.2.b.059 A common neurobiology for reward, chronic pain and depression? A [11C]raclopride bolus plus constant infusion PET-study by K. Ledermann; J. Jenewein; H. Sprott; G. Hasler; U. Schnyder; C. Burger; A. Johayem; S. Kollias; A. Buck; C. Martin-Soelch (S354).

P.2.b.060 Language phenomenon in the diagnostic criteria of mild depression by D. Smirnova; E. Sloeva; N. Kuvshinova; A. Krasnov; M. Ustinov; D. Romanov; G. Nosachev (S354-S355).

P.2.c.001 Mood disorder and obesity: policy and evidence revisited by A.E. Schmidt; E.Z. Reininghaus (S355-S356).

P.2.b.041 Depression, antidepressants and alcohol use affects suicidal ideation in primary care patients by V. Liaugaudaite; J. Peceliuniene; N. Raskauskiene; N. Mickuviene; R. Bunevicius (S343).

P.2.b.024 Efficacy of antidepressants in the treatment of major depressive disorder: a naturalistic study by A. Balagué Anó; M.V. Ollés; P. Gento; E. Turnes; J. Calvo (S332-S333).

P.2.b.025 Decrease of homocysteine levels after pharmacological treatment in patients with unipolar and bipolar depression by A. Permoda-Osip; J. Dorszewska; M. Chlopocka-Wozniak; J.K. Rybakowski (S333).

P.2.b.019 Clock gene polymorphisms and haplotypes in mood disorder in a Polish cohort by M. Wilkosc; M. Wegalrz; M. Maciukiewicz; J. Pawlak; A. Leszczynska-Rodziewicz; J. Hauser (S329-S330).

P.2.b.026 Social adjustment among therapy responder patients with mood disorders by A. Chiesa; A. Serretti; D. Souery; R. Calati; O. Sentissi; S. Kasper; E. Akimova; J. Zohar; D. Amital; S. Montgomery (S334).

P.2.b.036 BDNF: an indicator of insomnia? by M. Giese; E. Unternährer; H. Hüttig; J. Beck; S. Brand; P. Calabrese; E. Holsboer-Trachsler; A. Eckert (S340).

P.2.b.035 Metabolic syndrome and C-reactive protein in patients with depressive disorder on antidepressive medication by I. Popovic; D. Ravanic; A. Stanojevic; V. Popovic; S. Vladejic (S339-S340).

P.2.b.033 A randomized study of escitalopram and paroxetine controlled-release in the treatment of Japanese patients with major depressive disorder by T. Kishi; K. Kawashima; M. Moriwaki; Y. Otake; T. Mukai; Y. Matsuda; K. Fujita; N. Iwata (S338).

P.2.b.032 Neural correlates of emotion regulation response to negative stimuli in young women at high risk for depression by F. Simsek; O. Kaya; S. Akan; D. Haznedaroglu Isman; D. Acikel; O.M.E.R. Kitis; S. Cetinkalp; M. Eker; K. Coburn; A. Gonul (S337-S338).

P.1.j.016 Adulthood isolation stress enhances both long- and short-term potentiation in rats by B. Tan; F. Deneme; S. Bitiktas; S. Kavraal; M. Ascioglu; C. Suer (S290-S291).

P.1.h.003 Orexin A receptor antagonist SB-408124 attenuates the effect of amphetamine on the brain reward system by A.A. Lebedev; E.R. Bychkov; P.P. Khokhlov; E.G. Shumilov; R.O. Roik; P.D. Shabanov (S244).

P.1.h.004 Monoaminergic systems mature in rat offspring brain in pre- and early postnatal period after maternal alcoholisation by P.D. Shabanov; E.R. Bychkov; M.I. Airapetov; E.A. Sekste; R.O. Roik; A.A. Lebedev (S245).

P.1.h.005 Extended effects of chronic social stress on the behaviors of adolescents in adulthood by I.L. Kovalenko; D.A. Smagin; A.G. Galyamina; N.N. Kudryavtseva; G.N. Enikolopov (S245-S246).

P.1.h.006 Anti-allodynic effects of agomelatine combined with gabapentin in neuropathic rats with infraorbital nerve constriction by S. Bourgoin; B. Michot; N. Deraredj; M. Bertrand de Laujardière; C. Gabriel; E. Mocaër; M. Hamon (S246).

P.1.g.085 Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia – a 1-year non-interventional study by A. Schreiner; A. Svensson; R. Wapenaar; P. Cherubin; P. Princet; L. Serazetdinova; N. Starostina; M. Zink (S240).

P.1.g.084 Prevention of nicotine-induced kindling in female periadolescent rats by the repeated administration of N-acetylcysteine by C. Custodio; B.S.F. Mello; A.M.N. Costa; P.X.L. Gomes; G.V. Oliveira; F.Y.R. Araujo; F.C.F. Sousa; A.F. Carvalho; D.S. Macedo (S239-S240).

P.1.g.087 Hyperammonemic encephalopathy caused by combined electroconvulsive therapy and valproate use by G. Eryilmaz; C. Salcini; B. Onen Unsalver; I. Gogcegoz; E. Saglam (S241).

P.1.h.018 Acute methamphetamine exposure induces long-lasting depressive-like behavior in mice by C. Fontes Ribeiro; C. Silva; A.F. Neves; H.J. Freitas; A.I. Dias; S.M. Mendes; I. Pita; S.D. Viana; R. Prediger; F. Pereira (S253).

P.1.h.017 Regulation of the level of LSAMP gene and protein by alternative promoters in mouse brain and implications in behavioral models by M. Philips; K. Lilleväli; J. Innos; H. Luuk; C.A. Hundahl; I. Heinla; E. Vasar (S252-S253).

P.1.h.016 Robust and reproducible detection of distributed resting-state networks in the mouse brain by F. Sforazzini; A.J. Schwarz; A. Galbusera; A. Bifone; A. Gozzi (S252).

P.1.h.015 Differential effect of c-Fos activation associated with JNJ16259685 after an agonistic encounter as compared with grouped mice by V. De Castro; D. Suárez-Boomgaard; A. Rivera; M. Martín-López; J.F. Navarro (S251).

P.1.h.011 Studies on the effects of some Bidens tripartita extracts on psychomotor abilities in rats by R.B. Sandu; C.E. Lupusoru; R.V. Lupusoru; L. Tartau (S248-S249).

P.1.h.010 Early life influences on emotional reactivity, social behaviour and neuroinflammation by I. Gracia-Rubio; M. Moscoso-Castro; J. Ruiz-Medina; O. Valverde (S248).

P.1.h.013 Agomelatine induces antihyperalgesic effects in a rat model of neuropathic pain and produces an additive interaction with gabapentin by C. Chenaf; E. Chapuy; C. Courteix; F. Libert; M. Bertrandde Laujardière; C. Gabriel; E. Mocaër; A. Eschalier (S250).

P.1.h.014 The effects of mitochondrial mediators on spontaneous activity and balance by T. Alexa; A. Dondas; A. Luca; A. Negru; I. Stanciuc; C.E. Gherca; A. Mihai; C.R. Bohotin (S250-S251).

P.1.g.083 Determination of the alterations in prepulse inhibition in mice treated with doxycycline in an animal model of depression by B.S.F. Mello; C.S. Custodio; B.M.M. Ribeiro; R.C. Cordeiro; J.V. Santos; P.X.L. Gomes; F.C.F. Sousa; H.V. Nobre; A.F. Carvalho; D.S. Macedo (S238-S239).

P.1.g.064 Comparison of sensorimotor gating and quantitative EEG in serotonergic models of psychosis in the rat by F. Tyls; T. Palenicek; M. Fujakova; L. Kaderabek; P. Novakova; A. Kubesova; J. Horacek (S227).

P.1.g.065 Involvement of M2 muscarinic receptors of locus coeruleus in post-ictal antinociception by T. Paschoalin Maurin; R.C. De Oliveira; N.C. Coimbra (S227-S228).

P.1.g.066 The genetic deletion of the Lsamp gene in mice induces age-dependent changes in the phenotype by J. Innos; I. Aug; A. Bregin; T. Mazitov; M.A. Philips; E. Vasar (S228).

P.1.g.067 Tianeptine has neuroprotective effects in a differentiated SH-SY5Y human neuroblastoma cell line by G. Colpo; G.R. Fries; P. Ferrari; F. Klamt; F. Kapczinski (S229).

P.1.g.062 Reduction in serotonin 5-HT2C receptor antagonist-induced effects on theta power after chronic escitalopram treatment in rats by D. Kostyalik; Z. Kátai; S.Z. Vas; D. Pap; B. Horváth; I. Gyertyán; L. Tóthfalusi; G.Y. Bagdy (S225-S226).

P.1.g.056 A multireceptor ligand ACz37 representing a new series of arylpiperazine analogs with antipsychotic and antidepressant activity in mice by A. Wesolowska; A. Czopek; A. Partyka; A. Wasik; D. Wrobel; M. Jastrzebska-Wiesek; A. Zagorska; M. Kolaczkowski; M. Pawlowski (S222).

P.1.g.059 Effects of antiepileptic drugs on the physical working capacity of rats by M. Shishmanova; K. Georgieva; L. Peychev (S223-S224).

P.1.g.060 The effect of mesenchymal stem cells on allodynia, electrophysiologic and histologic parameters in an experimental neuropathy model by F. Aksu; O. Ergürhan Kiroglu; A. Alizadeh Yegani; E. Maytalman; M. Emre; S. Zorludemir; S. Mete (S224-S225).

P.1.g.069 Aberrant ligand–receptor dynamics of the muscarine-M1 agonist AF150(S) by J.E. Leysen; E.W.E. Verweij; M. Verlaan; K. De Waepenaert; I. Fonteyn; C.F.M. Molthoff; A. Fisher; A.D. Windhorst; H.J.C. Buiter; A.A. Lammertsma (S230).

P.1.g.078 Approaches to create dietary supplements to prevent postpartum depression by Y. Dowlati; A. Ravindran; Z. Segal; M. Steiner; J.H. Meyer (S235-S236).

P.1.g.077 Effects of clozapine on the prepulse inhibition of rats submitted to the model of schizophrenia induced by neonatal immune challenge by B.M.M. Ribeiro; C.S. Custodio; B.S.F. Mello; R.C. Cordeiro; J.V. Santos; A.T. Menezes; M.L. Vale; S.M.M. Vasconcelos; A.F. Carvalho; D.S. Macedo (S235).

P.1.g.079 Dopaminergic neurotransmission in clinical and genetic high risk populations for psychosis by T. Van Amelsvoort; O. Bloemen; E. Boot; M. De Koning; J. Booij (S236).

P.1.g.080 Modulation of cognitive function and 5-HT hippocampal levels in socially isolated rodents after peptidomimetic treatment by E. Encheva; L. Tancheva; L. Alova; V.V. Petkov; R. Klissurov; M. Novoselski; D. Tsekova; N. Belova (S237).

P.1.g.081 Zinc depletion impairs behaviour and alters trace elements profile in serum and brain structures by U. Doboszewska; B. Ostachowicz; B. Szewczyk; G. Nowak (S237-S238).

P.1.g.076 Determination of the immunoexpression of iNOS in the hippocampus of rats submitted to the Poly I:C-induced model of schizophrenia by B.M.M. Ribeiro; B.S.F. Mello; C.S. Custodio; P.X.L. Gomes; M.R.S. Carmo; M.L. Vale; A.T. Menezes; D.F. Lucena; S.M.M. Vasconcelos; D.S. Macedo (S234-S235).

P.1.g.075 Gender differences in routes of drug administration in involuntarily admitted patients – changes from 1997 to 2007 by A. Rauch; M. Edlinger; T. Wolfinger; G. Kemmler; N. Yalcin-Siedentopf; W.W. Fleischhacker; A. Hofer (S234).

P.1.g.071 Possible benefits of a combination of physical activity and levodopa administration in a rat model of Parkinson-like disease by C.S. Custodio; J.V. Santos; A.C.V. Gomes; R.C. Cordeiro; A.S. Monte; B.S.F. Mello; B.M.M. Ribeiro; L.D. Belchior; D.S. Macedo (S231-S232).

P.1.g.070 Dopaminergic and serotonergic dysfunctions induced by methamphetamine in mice are decreased by aerobic exercise by C.A. Fontes Ribeiro; A.F. Neves; H.J. Freitas; A.I. Dias; S.M. Mendes; S.D. Viana; S. Nunes; F.C. Pereira (S231).

P.1.g.072 Advantages of alpha-lipoic acid and physical training combination in a Parkinson-like disease animal model by B.S.F. Mello; J.V. Santos; A.C.V. Gomes; R.C. Cordeiro; A.S. Monte; C.S. Custodio; B.M.M. Ribeiro; L.D. Belchior; D.S. Macedo (S232).

P.1.g.073 Modulation of 5-HT-Ach interactions in the hippocampus by newly synthesised peptidomimetics in an experimental model of aggression in rats by R. Klisurov; E. Encheva; L. Tancheva; L. Shikova; L. Alova; M. Kaneva; D. Tsekova (S232-S233).

P.1.g.074 Plasma concentrations of paroxetine among treatment responder inpatients at week one and before discharge by G. Eryilmaz; M.E. Ceylan; B. Onen Unsalver; I. Gogcegoz; S. Ozilhan; E. Saglam (S233-S234).

P.1.h.022 Role of monoaminergic receptors in the panic-like behaviour evoked in Swiss mice by confrontation with wild coral snakes by R.L. De Freitas; L.V. Rimi; A.F. Biagioni; W.A. Ubiali; N.C. Coimbra (S255-S256).

P.1.h.023 The role of fibroblast growth factor antisense in modulation of affective behaviour by E. Eren-Kocak; M. Yilmaz; K. Basar; Y. Ayhan; H. Ozdemir; Z.D. Sen (S256).

P.1.i.028 Emotion processing in eating disorders: an fMRI study by R.M. Molina-Ruiz; M. Marina Díaz-Marsá; T. Tomás García Saiz; E. Esther Via; H. Helena Trebbau; M. Mariano Rincón (S279-S280).

P.1.i.027 The influence of cross-sex hormone therapy on motor inhibition measured with the stop signal task and 7Tesla fMRI by M. Spies; G.S. Kranz; S. Ganger; R. Sladky; M. Küblböck; T. Vanicek; A. Hahn; C. Windischberger; S. Kasper; R. Lanzenberger (S279).

P.1.i.029 Working memory (WM) assessment in euthymic bipolar patients: a 3T functional magnetic resonance imaging (fMRI) study with N-back task by L. Cremaschi; M. Cristoffanini; B. Penzo; M.C. Palazzo; C. Dobrea; C. Cinnante; S. Avignone; B. Dell'Osso; F.M. Triulzi; A.C. Altamura (S280).

P.1.j.001 Cognitive function in recovered geriatric depressive patients by B. Kim; J. Chang; D. Lee; J. Park (S281-S282).

P.1.i.026 Cortical thickness differences in methamphetamine dependent individuals with and without a history of psychosis by A. Uhlmann; N. Koen; H. Sinclair; H. Temmingh; E. Meintjes; D.J. Stein (S278-S279).

P.1.i.025 Abnormal brain functioning during salience processing in patients with schizophrenic psychosis by A. Walter; R. Smieskova; A. Schmidt; A. Simon; T. Vogel; J.P. Roiser; A. Riecher-Rössler; S. Borgwardt (S277-S278).

P.1.i.020 Grey matter volume abnormalities in adolescents at high risk for psychosis by G. Sugranyes; E. De la Serna; C. Espelt; A. Calvo; V. Sanchez-Gistau; O. Puig; S. Romero; M. Dolz; J. Castro-Fornieles; I. Baeza (S274-S275).

P.1.i.024 Simultaneous PET-MR imaging of the effects of microdose challenges using [11C]AZ-10419369 in non-human primates by H.D. Hansen; J. Mandeville; L. Feng; C.Y. Sander; J.M. Hooker; C. Catana; B. Rosen; G.M. Knudsen (S277).

P.1.j.003 Abnormal reward processing in the methylazoxymethanol (MAM) model of schizophrenia: neural and behavioural evidence by J. Francois; M. Conway; J. Huxter; J.P. Lowry; M. Tricklebank; G. Gilmour (S282-S283).

P.1.j.015 The neural basis of enhanced self-focus attention in patients with major depression by G. Wagner; C. Schachtzabel; U. Pietsch; G. Peikert; K.J. Bär (S290).

P.1.j.005 Association between cognitive function, disability, productivity and quality of life among patients treated for depression by J.L. Kurlander; J.S. Samp; K.S. Akhras; P. Maruff; L.R. Kingery; B. Essoi; V. Walker (S284).

P.1.j.006 Association between cognitive function and patient-reported depression severity among patients treated for depression by K.S. Akhras; J.C. Samp; J.L. Kurlander; V. Walker; L.R. Kingery; J. Jaeger; P. Maruff (S284-S285).

P.1.j.007 Impact of improved insight in schizophrenia: a double-blind lurasidone and quetiapine XR study by P. Harvey; C.O. Siu; J. Cucchiaro; A. Pikalov; A. Loebel (S285).

P.1.j.008 Computerised cognitive testing in the medical treatment of neurological and psychiatric disorders by K. Kurzbuch; W. Graf; B.S. Kasper; H. Stefan; E. Pauli (S285-S286).

P.1.i.019 Epistasis between catechol-O-methyltransferase and dopamine transporter genotypes on hippocampal volume in cannabis users and controls by A. Batalla; V. Lorenzetti; M. Yücel; C. Soriano-Mas; S. Bhattacharyya; R. Martín-Santos (S274).

P.1.i.018 Anterior cingulate cortex reactivity to emotion processing in premenstrual disphoric disorder by E. Comasco; A. Hahn; S. Ganger; M. Gingnell; E. Bannbers; L. Oreland; J. Wikström; R. Lanzenberger; I. Sundström-Poromaa (S273-S274).

P.1.h.031 The effects of intrathecal versus intraperitoneal vitamin C administration on pain models in mice by A. Luca; T. Alexa; A. Dondas; G.D. Andron; D. Negru; C.R. Bohotin (S260-S261).

P.1.i.002 Subgenual anterior cingulate cortical functional connectivity in treatment-resistant depression by C. Baeken; D. Marinazzo; G.R. Wu; P. Van Schuerbeek; J. De Mey; R. De Raedt (S262-S263).

P.1.i.003 PET brain imaging of neuropeptide Y2 receptors by D. Smith; M. Winterdahl; H. Audrain; A. Landau; P. Bonaventure; J. Shoblock; N. Carruthers; D. Swanson; D. Bender (S263-S264).

P.1.h.030 PWZ-029 alleviates MK-801-induced memory deficits in the rat: implications for the treatment of cognitive impairment in schizophrenia by S. Joksimovic; A.L. Obradovic; T. Timic; T. Radulovic; P. Biawat; J. Kovacevic; M. Milic; B. Batinic; J.M. Cook; M.M. Savic (S260).

P.1.h.029 MK-801-induced hyperlocomotion in rats is affected by modulation of α5-containing GABAA receptors by T. Timic; S. Joksimovic; A.L. Obradovic; M.M. Poe; P. Biawat; J. Ramerstorfer; B.L. Roth; W. Sieghart; J.M. Cook; M.M. Savic (S259-S260).

P.1.h.026 Effects of obestatin and its fragment (1–4) on algesthesia and behavioural activity in male wistar rats by E. Khirazova; M. Maslova; A. Guseva; A. Graf; A. Maklakova; N. Sokolova; A. Kamenskij; Z. Bespalova; D. Frid (S257-S258).

P.1.h.028 Selective antagonism at CRF1 receptor as a novel pharmacological treatment for binge-type eating disorders by M. Micioni Di Bonaventura; M. Ubaldi; K. Rice; M. Massi; R. Ciccocioppo; C. Cifani (S259).

P.1.i.004 Acute enhancement of serotonin neurotransmission with escitalopram on emotion processing: a randomized, crossover fMRI study by T. Outhred; P. Das; K.L. Felmingham; R.A. Bryant; P.J. Nathan; G.S. Malhi; A.H. Kemp (S264).

P.1.i.005 Acute neural effects of SSRIs versus NRIs on emotion processing: implications for differential treatment efficacy by T. Outhred; B.E. Hawkshead; T.D. Wager; P. Das; G.S. Malhi; A.H. Kemp (S264-S265).

P.1.i.014 Alterations of white matter microstructure in anorexia nervosa by E. Via; A. Zalesky; A. Fornito; I. García; L. Forcano; J. Pujol; F. Fernández-Aranda; J.M. Menchón; C. Soriano-Mas; N. Cardoner (S270-S271).

P.1.i.013 No effect of TPH1, MAO-A, 5-HT1A and 5-HT2A gene variants on 5-HT1A binding potential in healthy subjects measured with PET by P. Baldinger; M. Mitterhauser; M. Bilban; C. Kraus; J. Ungersboeck; M. Jeitler; W. Wadsak; D. Rujescu; S. Kasper; R. Lanzenberger (S270).

P.1.i.015 The effect of the brain-derived neurotrophic factor Val66Met polymorphism on human hippocampal volume – a meta-analysis by F. Harrisberger; R. Smieskova; A. Schmidt; A. Papassotiropoulos; S. Borgwardt (S271-S272).

P.1.i.017 Three week bright-light intervention has dose-related effects on threat-related corticolimbic reactivity and functional coupling by P.M. Fisher; M.K. Madsen; B. Mc Mahon; K.K. Holst; S.B. Andersen; H.R. Laursen; L.F. Hasholt; H.R. Siebner; G.M. Knudsen (S272-S273).

P.1.i.012 Habenular nuclei in different phases of major depressive disorder: a magnetic resonance imaging volumetric study by M. Carceller; M. Serra-Blasco; J. De Diego-Adeliño; Y. Vives-Gilabert; B. Gómez-Anson; D. Puigdemont; E. Álvarez; V. Pérez; M. Portella (S269-S270).

P.1.i.011 Prefrontal serotonin transporter binding is not associated with trait aggression and impulsivity in healthy subjects by S. Da Cunha-Bang; V. Frokjaer; B. McMahon; K. Holst; P. Jensen; G. Moos Knudsen (S268-S269).

P.1.i.007 The effect of bright light intervention on cerebral serotonin transporter binding by B. Mc Mahon; A.S. Andersen; L. Feng; M.K. Madsen; S. Lehel; M.M. Herth; P. Iversen; L. Hasholtd; G.M. Knudsen (S266).

P.1.i.006 Brain sonography as a novel method for detection of nuclei raphe lesion in suicidal patients and MDMA users by M. Budisic; D. Karlovic; D. Buljan; M. Strineka; V. Basic-Kes (S265-S266).

P.1.i.008 Bipolar disorder and magnetic resonance imaging by S.L. Romero Guillena; P. Aguilar Valseca; P. Vaquero Casado; E. Garcia Henche; B.O. Plasencia Garcia de Diego (S266-S267).

P.1.i.009 Default mode network alterations in refractory schizophrenia patients with auditory verbal hallucinations by A. Alonso-Solis; Y. Vives-Gilabert; E.M. Grasa; S. Durán-Sindreu; A. Keymer; A. Roldan; F. Nuñez-Marín; B. Gómez-Ansón; V. Perez; I. Corripio (S267-S268).